

References

Chapter 1

1. van Amsterdam JGC, Opperhuizen A, Koeter M et al (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. *European Addiction Research* **16**: 202-27.
2. Nutt DJ, King LA & Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. *The Lancet* **376**: 1558-65.
3. British Medical Association (1997) *The misuse of drugs*. London: British Medical Association.
4. British Medical Association (1997) *Therapeutic uses of cannabis*. London: British Medical Association.
5. British Medical Association (2003) *Adolescent health*. London: British Medical Association.
6. British Medical Association (2005) *Over-the-counter medication*. London: British Medical Association.
7. British Medical Association (2006) *Child and adolescent mental health*. London: British Medical Association.
8. British Medical Association (2006) *Legalising illicit drugs: a signposting resource*. London: British Medical Association.
9. British Medical Association (2009) *Driving under the influence of drugs*. London: British Medical Association.
10. Ministry of Health (1926) *Report of the Departmental Committee on Morphine and Heroin Addiction (The Rolleston Report)*. London: Her Majesty's Stationery Office.
11. World Health Organization (2007) *International statistical classification of diseases and related health problems, 10th revision (2e)*. Geneva: World Health Organization.
12. American Psychiatric Association (1994) *Diagnostic and statistical manual of mental disorders (4e)*. Washington: American Psychiatric Association.
13. Volkow ND & Li TK (2004) Drug addiction: the neurobiology of behaviour gone awry. *Nature Reviews Neuroscience* **5**: 963-70.
14. Koob GF (2006) The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. *Addiction* **101** (suppl 1): 23-30.
15. Casey BJ & Jones RM (2010) Neurobiology of the adolescent brain and behaviour: implications for substance use disorders. *Journal of the American Academy of Child and Adolescent Psychiatry* **49**: 1189-201.
16. Newton NC, O'Leary-Barrett M & Conrod PJ (2013) Adolescent substance misuse. Neurobiology and evidence based interventions. *Current Topics in Behavioural Neurosciences* **13**: 685-708.
17. Dall D (2008) Addiction science and its genetics. *Addiction* **103**: 360-7.
18. Kimura M & Higuchi S (2011) Genetics of alcohol dependence. *Psychiatry and Clinical Neurosciences* **65**: 213-25.
19. Goldman D, Oroszi G & Ducci F (2005) The genetics of addictions: uncovering the genes. *Nature Reviews Genetics* **6**: 521-32.
20. House of Commons Science and Technology Select Committee *Drug classification: making a hash of it: fifth report of session 2005-2006*. HC 1031. 2005-6.
21. Home Office press release (21.07.11) *Import ban of new 'legal high' phenazepam introduced*.
22. Home Office press release (01.11.12) *Mexxy, Black Mamba and other 'legal highs' to be banned*.
23. Home Office press release (28.03.12) *First 'legal high' to be banned under new powers*.

Chapter 2

1. Davies C, English L, Stewart C et al (2011) *United Kingdom drug situation: annual report to the European monitoring centre for drugs and drug addiction (EMCDDA)*. London: United Kingdom Focal Point at the Department of Health.
2. European Monitoring Centre for Drugs and Drug Addiction (2011) *Annual report on the state of the drugs problem in Europe*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
3. Hoare J & Moon D (eds) (2010) *Drug misuse declared: findings from the 2009/10 British Crime Survey. England and Wales*. London: Home Office.

4. Home Office (2012) *Drug misuse declared: findings from the 2011/2012 British Crime Survey, England and Wales* (2e). London: Home Office.
5. The Scottish Government (2012) *2010-11 Scottish crime and justice survey: drug use*. Edinburgh: The Scottish Government.
6. Department of Justice (2010) *Experience of drug misuse: findings from the 2008/09 Northern Ireland Crime Survey*. Belfast: Department of Justice.
7. Hay G, Gannon M, Casey J et al (2011) *Estimates of the prevalence of opiate use and/or crack cocaine use, 2009/10: Sweep 6 report*. Glasgow: University of Glasgow.
8. Fuller E (2012) *Smoking, drinking and drug use amongst young people in England 2011*. London: Information Centre for Health and Social Care.
9. Currie C, Gabhainn SN, Godeau E et al (2008) *Inequalities in young people's health: international report from the 2005/2006 survey*. Copenhagen: World Health Organization Europe.
10. Hibell B, Guttormsson U, Ahlström S et al (2009) *The 2007 ESPAD report. Substance use among students in 35 European Countries*. Stockholm: Swedish Council for Information on Alcohol and Other Drugs.
11. Measham F, Moore K, Newcombe R et al (2010) Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. *Drugs and Alcohol Today* **10**: 14-21.
12. Newcombe R (2004) *Attitudes to drug policy and drug laws: a review of the international evidence*. Liverpool: 3D Research Bureau.
13. British Medical Association (1997) *Therapeutic uses of cannabis*. London: British Medical Association.
14. Royal Society for the encouragement of Arts, Manufactures and Commerce (2007) *Drugs – facing facts. The report of the RSA commission on illegal drugs, communities and public policy*. London: Royal Society for the Encouragement of Arts, Manufactures and Commerce.
15. YouGov (2011) *The drugs (policies) don't work*. London: YouGov.
16. Bailey R, Fuller E & Ormston R (2010) Smoking, drinking and drugs: reaction to reform. In: Park A, Curtice J Thomson K et al (eds) *Britsocial attitudes. The 26th report*. London: National Centre for Social Research.
17. Scottish Government (2010) *Scottisocial attitudes survey 2009: public attitudes to drugs and drug use in Scotland*. Edinburgh: Scottish Government.
18. United Nations Office on Drugs and Crime (2012) *World drug report 2012*. Vienna: United Nations Office on Drugs and Crime.

Chapter 3

1. Babor T, Caulkins J, Edwards G et al (2010) *Drug policy and the public good*. Oxford: Oxford University Press.
2. Nutt DJ, King LA & Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. *The Lancet* **376**: 1558-65.
3. Hall WD, Room R & Bondy S (1999) Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In: Kalant H, Corrigal W, Hall W et al (eds) *The health effects of cannabis*. Toronto: Addiction Research Foundation.
4. Roques B (1999) *La dangerosité de drogues: rapport au Secrétariat d'Etat à la Santé*. Paris: La Documentation Française-Odile Jacob.
5. Best D, Gross S, Vingoe L et al (2003) *Dangerousness of drugs: a guide to the risks and harms associated with substance use*. London: Department of Health.
6. Gable RS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction* **99**: 686-96.
7. Nutt DJ, King LA, Saulsbury W et al (2007) Development of a rational scale to assess the harm of drugs of potential misuse. *The Lancet* **369**: 1047-53.
8. van Amsterdam JGC, Opperhuizen A, Koeter M et al (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. *European Addiction Research* **16**: 202-27.
9. Rolles S & Measham F (2011) Questioning the method and utility of ranking drug harms in drug policy. *International Journal of Drug Policy* **22**: 243-6.
10. Caulkins JP, Reuter P & Coulson C (2011) Basing drug scheduling decisions on scientific ranking of harmfulness: false promise from false premises. *Addiction* **106**: 1886-90.

11. Fischer B & Kendall P (2011) Nutt et al.'s harm scales for drugs: room for improvement but better policy based on science with limitations than no science at all. *Addiction* **106**: 1891-2.
12. Nutt D (2011) Let not the best be the enemy of the good: a reply to Caulkins et al. *Addiction* **106**: 1892-3.
13. Rossow I (2011) Can harm ratings be useful? *Addiction* **106**: 1893-4.
14. Obot IS (2011) Improved rankings of drugs on harmfulness can bring sense and order to a failed system. *Addiction* **106**: 1894-5.
15. Room R (2011) Scales and blinkers, motes and beams: whose view is obstructed on drug scheduling? *Addiction* **106**: 1895-6.
16. Brown VL & Riley MA (2005) Social support, drug use, and employment among low-income women. *American Journal of Drug and Alcohol Abuse* **31**: 203-23.
17. Davies C, English L, Stewart C et al (2011) *United Kingdom drug situation: annual report to the european monitoring centre for drugs and drug addiction (EMCDDA) 2011*. London: United Kingdom Focal Point at the Department of Health.
18. Hser YI, Hoffman V, Grella CE et al (2001) A 33-year follow up of narcotics addicts. *Archives of General Psychiatry* **58**: 503-8.
19. Darke S & Hall W (2003) Heroin overdose: research and evidence-based intervention. *Journal of Urban Health* **80**: 189-200.
20. Degenhardt L, Hall W, Warner-Smith M et al (2004) Illicit drug use. In: Ezzati M, Lopez AD, Rogers A et al (eds) *Comparative quantification of health risks. bal and regional burden of disease attributable to selected major risk factors*. Geneva: World Health Organization.
21. Darke S, Degenhardt L & Mattik R (2007) *Mortality amongst illicit drug users: epidemiology, causes and intervention*. Cambridge: Cambridge University Press.
22. O'Driscoll P, McGough J, Hogan H et al (2001) Predictors of accidental fatal drug overdose among a cohort of injection drug users. *American Journal of Public Health* **92**: 984-7.
23. Warner-Smith M, Darke S, Lynskey M et al (2001) Heroin overdose: causes and consequences. *Addiction* **96**: 1113-25.
24. Latt N, Conigrave K, Saunders JB et al (2009) *Addiction medicine*. Oxford: Oxford University Press.
25. Winger G, Woods JH & Hofmann FG (2004) *A handbook on drug and alcohol abuse – the biomedical aspects*. New York: Oxford University Press.
26. Jones L, Bates G, Bellis M et al (2011) *A summary of the health harms of drugs*. London: Department of Health.
27. Favrod-Coune T & Broers B (2010) The health effect of psychostimulants: a literature review. *Pharmaceuticals* **3**: 2333-61.
28. McKinney E & Palmer RB (2005) Amphetamines and derivatives. In: Brent JB, Wallace KL, Burkhardt KK et al (eds) *Critical care toxicology*. Philadelphia: Elsevier.
29. Advisory Council on the Misuse of Drugs (2005) *Methylamphetamine review*. London: Advisory Council on the Misuse of Drugs.
30. Schifano F, Corkery J, Naidoo V et al (2010) Overview of amphetamine-type stimulant mortality data – UK, 1997-2007. *Neuropsychobiology* **61**: 122-30.
31. Singleton J, Degenhardt L, Hall W et al (2009) Mortality among amphetamine users: a systematic review of cohort studies. *Drug and Alcohol Dependence* **105**: 1-8.
32. McKetin R, McLaren J, Lubman DI et al (2006) The prevalence of psychotic symptoms among methamphetamine users. *Addiction* **101**: 1473-8.
33. Moon M, Do KS, Park J et al (2007) Memory impairment in methamphetamine dependent patients. *International Journal of Neuroscience* **117**: 1-9.
34. Newton TF, Kalechstein AD, Duran S et al (2004) Methamphetamine abstinence syndrome: preliminary findings. *American Journal on Addictions* **13**: 248-55.
35. Srisurapanont M, Ali R, Marsden J et al (2003) Psychotic symptoms in methamphetamine psychotic inpatients. *International Journal of Neuropsychopharmacology* **6**: 347-52.
36. Scott JC, Woods SP, Matt GE et al (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. *Neuropsychology Review* **17**: 275-97.
37. Mehra R, Moore BA, Crothers K et al (2006) The association between marijuana smoking and lung cancer: a systematic review. *Archives of Internal Medicine* **166**: 1359-67.
38. Aldington S, Harwood M, Cox B et al (2008) Cannabis use and risk of lung cancer: a case-control study. *European Respiratory Journal* **31**: 280-6.

39. Hall W (2009) The adverse health effects of cannabis use: what are they, and what are their implications for policy? *The International Journal of Drug Policy* **20**: 458-66.
40. Hall W & Deegenhardt L (2009) Adverse health effects of non-medical cannabis use. *The Lancet* **374**: 1383-91.
41. Fried PA, Watkinson B & Gray R (2005) Neurocognitive consequences of marihuana – a comparison with pre-drug performance. *Neurotoxicology and Teratology* **27**: 231-9.
42. Kuepper R, Van Os J, Lieb R et al (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *British Medical Journal* **342**: d738.
43. Semple DM, McIntosh AM & Lawrie SM (2005) Cannabis as a risk factor for psychosis: systematic review. *Journal of Psychopharmacology* **19**: 187-94.
44. Advisory Council on the Misuse of Drugs (2008) *Cannabis: classification and public health*. London: Home Office.
45. Arseneault L, Cannon M, Witton J et al (2004) Causal association between cannabis and psychosis: examination of the evidence. *British Journal of Psychiatry* **184**: 110-7.
46. Rubino T, Zamberletti E & Parolaro D (2012) Adolescent exposure to cannabis as a risk factor for psychiatric disorders. *Journal of Psychopharmacology* **26**: 177-88.
47. Tjissen MJA, Van Os J, Wittchen HU et al (2010) Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community. *Acta Psychiatrica Scandinavica* **122**: 255-66.
48. Macleod J, Oakes R, Copello A et al (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. *The Lancet* **363**: 1579-88.
49. Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proceedings of the National Academy of Sciences* **109**: 15970-71.
50. McCord J, Jneid H, Hollander JE et al (2008) Management of cocaine-associated chest pain and myocardial infarction. A scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. *Circulation* **117**: 1897-907.
51. Qureshi AI, Suri MF, Guterman LR et al (2001) Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the third national health and nutrition examinations survey. *Circulation* **103**: 502-6.
52. Darke S, Kaye S & Dufflou J (2006) Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. *Addiction* **101**:1771-7.
53. Kaye S & Darke S (2004) Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. *Addiction* **99**: 1315-22.
54. Alaraj A, Wallace A, Mander N et al (2010) Effect of acute cocaine use on vasospasm and outcome in aneurysmal subarachnoid hemorrhage. *World Neurosurgery* **73**: 357-60.
55. Aslibekyan S, Levitan EB, Mittleman MA et al (2008) Prevalent cocaine use and myocardial infarction. *American Journal of Cardiology* **102**: 966-9.
56. Bamberg F, Schlett CL, Truong QA et al (2009) Presence and extent of coronary artery disease by cardiac computed tomography and risk for acute coronary syndrome in cocaine users among patients with chest pain. *American Journal of Cardiology* **103**: 620-5.
57. Hsue PY, McManus D, Selby V et al (2007) Cardiac arrest in patients who smoke crack cocaine. *American Journal of Cardiology* **99**: 822-4.
58. Kaye S & Darke S (2004) Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity. *Drug and Alcohol Review* **23**: 391-8.
59. Satran A, Bart BA, Henry CR et al (2005) Increased prevalence of coronary artery aneurysms among cocaine users. *Circulation* **111**: 2424-9.
60. Phillips K, Luk A, Soor GS et al (2009) Cocaine cardiotoxicity. A review of the pathophysiology, pathology, and treatment options. *American Journal of Cardiovascular Drugs* **9**: 177-196.
61. Schwartz BG, Rezkalla S & Kloner RA (2010) Cardiovascular effects of cocaine. *Circulation* **122**: 2558-69.
62. European Monitoring Centre for Drugs and Drug Addiction (2007) *Cocaine and crack cocaine: a growing public health issue*. Luxembourg: Office for Official Publications of the European Communities.
63. Darke S, Kaye S & Dufflou J (2005) Cocaine related fatalities in New South Wales, Australia 1993-2002. *Drug and Alcohol Dependence* **77**: 107-14.

64. Egred M & Davis GK (2005) Cocaine and the heart. *Postgraduate Medical Journal* **81**: 568-71.
65. Gowing LR, Henry-Edwards SM, Irvine RJ et al (2002) The health effects of ecstasy: a literature review. *Drug and Alcohol Review* **21**: 53-63.
66. Rogers G, Elston J, Garside R et al (2009) The harmful health effects of recreational ecstasy: a systematic review of observational evidence. *Health Technology Assessment* **13**: 1-315.
67. Forsyth AJM (2001) Distorted? A quantitative exploration of drug fatality reports in the popular press. *International Journal of Drug Policy* **12**: 435-53.
68. Advisory Council on the Misuse of Drugs (2008) *MDMA ('ecstasy'): a review of its harms and classification under the Misuse of Drugs Act 1971*. London: Home Office.
69. Degenhardt L & Hall W (2010) *The health and psychological effects of 'ecstasy' (MDMA) use*. Sydney: National Drug and Alcohol Research Centre.
70. Fisk JE, Montgomery C & Murphy PN (2009) The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users. *Experimental and Clinical Psychopharmacology* **17**: 326-36.
71. Halpern JH, Sherwood AR, Hudson JI et al (2011) Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. *Addiction* **106**: 777-86.
72. Gonzalez A & Nutt DJ (2005) Gamma hydroxy butyrate abuse and dependency. *Journal of Psychopharmacology* **19**: 195-204.
73. Degenhardt L, Darke S & Dillon P (2003) The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. *Addiction* **98**: 199-204.
74. Wood DM, Brailsford AD & Dargan PI (2011) Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). *Drug Testing and Analysis* **3**: 417-25.
75. Hillebrand J, Olszewski D & Sedefov R (2008) *GHB and its precursor : an emerging trend case study*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
76. Miotto K, Darakjian J, Basch J et al (2001) Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. *American Journal on Addictions* **10**: 232-41.
77. Degenhardt L, Darke S & Dillon P (2002) GHB use among Australians: characteristics, use patterns and associated harm. *Drug and Alcohol Dependence* **67**: 89-94.
78. Dyer J, Roth B & Hyma B (2001) Gamma-hydroxybutyrate withdrawal syndrome. *Annals of Emergency Medicine* **37**: 147-53.
79. Hickman M, Carnwath Z, Madden P et al (2003) Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. *Journal of Urban Health* **80**: 274-87.
80. Smyth B, Hoffman V, Fan J et al (2007) Years of potential life lost among heroin addicts 33 years after treatment. *Preventive Medicine* **44**: 369-74.
81. Advisory Council on the Misuse of Drugs (2004) *Report on ketamine*. London: Advisory Council on the Misuse of Drugs.
82. Chu PSK, Ma WK, Wong SCW et al (2008) The destruction of the lower urinary tract by ketamine abuse: a new syndrome? *British Journal of Urology International* **102**: 1616-22.
83. Cottrell AM, Athreeres R, Weinstock P et al (2008) Urinary tract disease associated with chronic ketamine use. *British Medical Journal* **336**: 973.
84. Shahani R, Streutker C, Dickson B et al (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. *Urology* **69**: 810-2.
85. European Monitoring Centre for Drugs and Drug Addiction (2009) *Polydrug use: patterns and responses*. Luxembourg: Office for Official Publications of the European Communities.
86. Cruts G, Buster M, Vicente J et al (2008) Estimating the total mortality among problem drug users. *Substance Use and Misuse* **43**: 733-47.
87. Hollander JE, Hoffman RS, Burstein JL et al (1995) Cocaine-associated myocardial infarction: mortality and complications. *Archives of Internal Medicine* **155**: 1081-6.
88. Baumann BM, Perrone J, Hornig SE et al (2000) Cardiac and hemodynamic assessment of patients with cocaine-associated chest pain syndromes. *Journal of Toxicology – Clinical Toxicology* **38**: 283-90.
89. British Medical Association (2007) *Fetal alcohol spectrum disorders – a guide for healthcare professionals*. London: British Medical Association.
90. British Medical Association (2004) *Smoking and reproductive life – the impact of smoking on sexual, reproductive and child health*. London: British Medical Association.

91. Addis A, Moretti ME, Ahmed Syed F et al (2001) Fetal effects of cocaine: an updated meta-analysis. *Reproductive Toxicology* **15**: 341-69.
92. Gouin K, Murphy K, Shah PS et al (2011) Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. *American Journal of Obstetrics and Gynecology* **204**: 340e1-12.
93. Cole C, Jones L, McVeigh J et al (2010) *CUT: a guide to adulterants, bulking agents and other contaminants found in illicit drugs*. Liverpool: Centre for Public Health, Liverpool John Moores University.
94. Cole C, Jones L, McVeigh J et al (2011) Adulterants in illicit drugs: a review of empirical evidence. *Drug Testing and Analysis* **3**: 89-96.
95. Presanis AM, Gill ON, Chadborn TR et al (2010) Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. *AIDS* **24**: 2849-58.
96. Department of Health (2002) *Getting ahead of the curve: a strategy for combating infectious diseases (including other aspects of health protection)*. A report by the Chief Medical Officer. London: Department of Health.
97. Aldington S, Williams M, Nowitz M et al (2007) Effects of cannabis on pulmonary structure, function and symptoms. *Thorax* **62**: 1058-63.
98. Forrester JM, Steele AW, Waldron JA et al (1990) Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. *American Review of Respiratory Disease* **142**: 462-7.
99. Kissner DG, Lawrence WD, Selis JE (1987) Crack lung: pulmonary disease caused by cocaine abuse. *American Review of Respiratory Disease* **136**: 1250-2.
100. Restrepo CS, Carrillo JA, Martínez S et al (2007) Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. *Radiographics* **27**: 941-56.
101. McCord J, Jneid H, Hollander JE et al (2008) Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. *Circulation* **117**: 1897-907.
102. DeSimone J (2002) Illegal drug use and employment. *Journal of Labour Economics* **20**: 952-9.
103. Zlotnick C, Robertson MJ & Tam T (2002) Substance use and labor force participation among homeless adults. *American Journal of Drug and Alcohol Abuse* **28**: 37-53.
104. Gilvavy E & Crome I (2004) Implications of parental substance misuse. In: Crome I, Ghodse H, Gilvavy E et al (eds) *Young people and substance misuse*. Gaskell: Royal College of Psychiatry.
105. Bancroft A, Wilson S, Cunningham-Burley S et al (2004) *Parental drug and alcohol misuse. Resilience and transition among young people*. York: Joseph Rowntree Foundation.
106. Advisory Council on the Misuse of Drugs (2003) *Hidden harms*. London: Home Office.
107. Home Office Statistical Bulletin (2007) *The arrestee survey 2003-2006*. London: Home Office.
108. Prime Minister's Strategy Unit (2003) *Strategy unit drugs report. Phase one – understanding the issues*. London: Prime Minister's Strategy Unit.
109. Home Office (2004) *Paying the price. A consultation paper on prostitution*. London: Home Office Communication Directorate.
110. Kuhns JB & Klodfelter TA (2009) Illicit drug-related psychopathological violence: the current understanding within a causal context. *Aggression and Violent Behaviour* **14**: 69-78.
111. Tyner EA & Fremouw WJ (2008) The relation of methamphetamine use and violence: a critical review. *Aggression and Violent Behavior* **13**: 285-97.
112. Kübler D & Wälti S (2001) Metropolitan governance and democracy: how to evaluate new tendencies? In: Mclaverty P (ed) *Public participation and developments in community governance*. Aldershot: Ashgate.
113. Everest JT, Tunbridge RJ & Widdop B (1989) *The incidence of drugs in road traffic accident fatalities*. Crowthorne: Transport and Road Research Laboratory.
114. Tunbridge RJ, Keigan M & James FJ (2001) *The incidence of drugs and alcohol in road accident fatalities*. Berkshire: Transport Research Laboratory.
115. Officer J (2009) Trends in drug use of Scottish drivers arrested under Section 4 of the Road Traffic Act – a 10 year review. *Science and Justice* **49**: 237-41.
116. European Monitoring Centre for Drugs and Drug Addiction (2008) *Drug use, impaired driving and traffic accidents. EMCDDA Insights Series No 8*. Luxembourg: Office for Official Publications of the European Communities.

117. Vis AA (1988) *Use of alcohol and drugs among road accidents victims*. Proceedings of 11th World Congress of the International Association for Accident and Traffic Medicine, 24-28 May, Dubrovnik.
118. Mathijssen MPM, Movig KLL, de Gier JJ et al (2002) *Use of psychoactive medicines and drugs as a cause of road trauma*. Proceedings of the 16th International Conference on Alcohol, Drugs and Traffic Safety, 4-9 August, Montreal.
119. Singleton N, Murray R & Tinsley L (2006) *Measuring different aspects of problem drug use: methodological developments*. London: Home Office.
120. The Health and Social Care Information Centre (2011) *Statistics on drug misuse: England, 2011*. London: Health and Social Care Information Centre.
121. Prime Minister's Strategy Unit (2003) *Strategy unit drugs report. Phase one – understanding the issues*. London: Cabinet Office.
122. Scottish Government (2008) *The road to recovery: a new approach to tackling Scotland's drug problem*. Edinburgh: Scottish Government.
123. Welsh Assembly Government (2008) *Working together to reduce harm. The substance misuse strategy for Wales 2008-2018*. Cardiff: Welsh Assembly Government.

Chapter 4

1. Babor T, Caulkins J, Edwards G et al (2010) *Drug policy and the public good*. Oxford: Oxford University Press.
2. World Health Organization (2004) *Neuroscience of psychoactive substance use and dependence*. Geneva: World Health Organization.
3. Li D, Zhao H & Gelernter J (2012) Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. *Human Genetics* **131**: 725-37.
4. Bierut LJ, Dinwiddie SH, Begleiter H et al (1998) Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. *Archives of General Psychiatry* **55**: 982-8.
5. Merikangas KR, Stolar M, Stevens DE et al (1998) Familial transmission of substance use disorders. *Archives of General Psychiatry* **55**: 973-9.
6. Agrawal A & Lynskey MT (2008) Are there genetic influences on addiction: evidence from family, adoption and twin studies. *Addiction* **103**: 1069-81.
7. Cadoret RJ, Yates WR, Ed T et al (1995) Adoption study demonstrating two genetic pathways to drug abuse. *Archives of General Psychiatry* **52**: 42-52.
8. Yokoyama A, Muramatsu T, Ohmori T et al (1998) Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. *Carcinogenesis* **19**:1383-7.
9. Agrawal A & Lynskey MT (2006) The genetic epidemiology of cannabis use, abuse and dependence. *Addiction* **101**: 801-12.
10. Tsuang MT, Lyons MJ, Eisen SA et al (1996) Genetic influences on DSM-R drug abuse and dependence: a study of 3,372 twin pairs. *American Journal of Medical Genetics* **67**: 473-7.
11. Tsuang MT, Lyons MJ, Meyer JM et al (1998) Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. *Archives of General Psychiatry* **55**: 967-72.
12. Kendler KS & Prescott CA (1998) Cocaine use, abuse and dependence in a population-based sample of female twins. *British Journal of Psychiatry* **173**: 345-50.
13. Kendler KS, Karkowski L, Prescott C et al (1999) Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins. *Acta Psychiatrica Scandinavica* **99**: 368-76.
14. Conway KP, Compton W, Stinson FS et al (2006) Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Journal of Clinical Psychiatry* **67**: 247-57.
15. Compton WM, Conway KP, Stinson FS et al (2005) Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Journal of Clinical Psychiatry* **66**: 677-85.
16. Hasin DS, Stinson FS, Ogburn E et al (2007) Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry* **64**: 830-42.

17. Glantz MD, Anthony JC, Berglund PA et al (2009) Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. *Psychological Medicine* **39**: 1365-77.
18. Swendsen J & Le Moal M (2011) Individual vulnerability to addiction. *Annals of the New York Academy of Sciences* **1216**: 73-85.
19. Latt N, Conigrave K, Saunders JB et al (2009) *Addiction medicine*. Oxford: Oxford University Press.
20. Fried PA, Watkinson B & Gray R (2005) Neurocognitive consequences of marihuana – a comparison with pre-drug performance. *Neurotoxicology and Teratology* **27**: 231-9.
21. Kuepper R, Van Os J, Lieb R et al (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *British Medical Journal* **342**: d738.
22. Semple DM, McIntosh AM & Lawrie SM (2005) Cannabis as a risk factor for psychosis: systematic review. *Journal of Psychopharmacology* **19**: 187-94.
23. Advisory Council on the Misuse of Drugs (2008) *Cannabis: classification and public health*. London: Home Office.
24. Arseneault L, Cannon M, Witton J et al (2004) Causal association between cannabis and psychosis: examination of the evidence. *British Journal of Psychiatry* **184**: 110-7.
25. Smith MJ, Thirthalli J, Abdallah AB et al (2009) Prevalence of psychotic symptoms in substance users: a comparison across substances. *Comprehensive Psychiatry* **50**: 245-50
26. Neale MC & Kendler KS (1995) Models of comorbidity for multifactorial disorders. *American Journal of Human Genetics* **57**: 935-53.
27. Swendsen JD, Conway KP, Rounsaville BJ et al (2002) Are personality traits familial risk factors for substance use disorders? Results of a controlled family study. *American Journal of Psychiatry* **159**: 1760-6.
28. Zuckerman M (1994) *Behavioural expressions and biosocial bases of sensation seeking*. Cambridge: Cambridge University Press.
29. Staiger PK, Kambouropoulos N & Dawe S (2007) Should personality traits be considered when refining substance misuse treatment programmes? *Drug and Alcohol Review* **26**: 17-23.
30. Dawe S, Gullo MJ & Loxton NJ (2004) Reward drive and rash impulsiveness as dimensions of impulsivity: implications for substance misuse. *Addictive Behaviors* **29**: 1389-405
31. Tarter RE, Kirisci L, Habeych M et al (2004) Neurobehaviour disinhibition in childhood predisposes boys to substance use disorder by young adulthood: direct and mediated etiologic pathways. *Drug and Alcohol Dependence* **73**: 121-32.
32. Uhl GR (2004) Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan results. *Annals of the New York Academy of Sciences* **1025**: 1-13
33. West R (2006) *Theory of addiction*. London: Blackwell Publishing.
34. Schulteis G & Koob G (1996) Reinforcement processes in opiate addiction: a homeostatic model. *Neurochemical Research* **21**: 1437-54.
35. Wanigaratne S (2006) Psychology of addiction. *Psychiatry* **5**: 455-60.
36. Drummond DC, Cooper T & Glautier SP (1990) Conditioned learning in alcohol dependence: implications for cue exposure treatment. *British Journal of Addiction* **85**: 725-43.
37. Hopfer CJ, Crowley TJ & Hewitt JK (2003) Review of twin and adoption studies of adolescent substance use. *Journal of the American Academy of Child and Adolescent Psychiatry* **42**: 710-9.
38. Rende R & Slomkowski C (2009) Incorporating the family as a critical context in genetic studies of children: implications for understanding pathways to risky behavior and substance use. *Journal of Pediatric Psychology* **34**: 606-16.
39. McArdle P, Wiegersma A, Gilvarry E et al (2002) European adolescent substance use: the roles of family structure, function and gender. *Addiction* **97**: 329-36.
40. Kuntsche EN & Silbereisen RK (2004) Parental closeness and adolescent substance use in single and two-parent families in Switzerland. *Swiss Journal of Psychology* **63**: 85-92.
41. Levy SJ & Pierce JP (1990) Predictors of marijuana use and uptake among teenagers in Sydney, Australia. *Substance Use and Misuse* **25**: 1179-93.
42. von Sydow K, Lieb R, Pfister H et al (2002) What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug and Alcohol Dependence* **68**: 49-64.

43. Kokkevi A, Richardson C, Florescu S et al (2007) Psychosocial correlates of substance use in adolescence: a cross-national study in six European countries. *Drug and Alcohol Dependence* **86**: 67-74.
44. Ledoux S, Miller P, Choquet M et al (2002) Family structure, parent-child relationships, and alcohol and other drug use among teenagers in France and the United Kingdom. *Alcohol and Alcoholism* **37**: 52-60.
45. Best D, Gross S, Manning V et al (2005) Cannabis use in adolescents: the impact of risk and protective factors and social functioning. *Drug and Alcohol Review* **24**: 483-8.
46. McVie S & Holmes L (2005) *Family functioning and substance use at ages 12 to 17*. Edinburgh: Centre for Law and Society.
47. McKeganey N, McIntosh J, MacDonald F et al (2004) Preteen children and illegal drugs. *Drugs: Education, Prevention and Policy* **11**: 315-27.
48. McVie S & Holmes L (2005) *Adolescent smoking, drinking and drug use at ages 12 to 17*. Edinburgh: Edinburgh Study of Youth Transitions and Crime Research Digest.
49. McKeganey N & Norrie J (1999) Pre-teen drug users in Scotland. *Addiction Research and Theory* **7**: 493-507.
50. Sutherland I & Shepherd JP (2001) Social dimensions of adolescent substance use. *Addiction* **96**: 445-58.
51. Stattin H & Kerr M (2000) Parental monitoring: a reinterpretation. *Child Development* **4**: 1072-85.
52. Kuntsche E & Jordan MD (2006) Adolescent alcohol and cannabis use in relation to peer and school factors: Results of multilevel analyses. *Drug and Alcohol Dependence* **84**: 167-74.
53. McIntosh J, MacDonald F & McKeganey N (2006) Why do children experiment with illegal drugs? The declining role of peer pressure with increasing age. *Addiction Research and Theory* **14**: 275-87.
54. Gage JC, Overpeck MD, Nansel TR et al (2005) Peer activity in the evenings and participation in aggressive and problem behaviors. *The Journal of Adolescent Health* **37**: 517.e7-e14.
55. Turner K, West P, Gordon J et al (2006) Could the peer group explain school differences in pupil smoking rates? An exploratory study. *Social Science and Medicine* **62**: 2513-25.
56. McVie S & Norris PA (2006) *Neighbourhood effects on youth delinquency and drug use*. Edinburgh: Edinburgh Study of Youth Transitions and Crime Research Digest.
57. North West Public Health Observatory (2010) *Indications of public health in the English regions. 10. Drug use*. Liverpool: North West Public Health Observatory.
58. NHS Scotland (2008) *Young people and substance use. The influence of personal, social and environmental factors on substance use among adolescents in Scotland*. Edinburgh: NHS Scotland.
59. Marmot M, Allen J, Goldblatt P et al (2010) *Fair society, healthy lives*. London: The Marmot Review.
60. European Monitoring Centre for Drugs and Drug Addiction (2008) *Drugs and vulnerable groups of young people*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
61. National Collaborating Centre for Drug Addiction (2005) *Drug prevention among vulnerable young people*. Liverpool: National Collaborating Centre for Drug Addiction.
62. Ward J (1998) Substance use among young people 'looked after' by social services. *Drugs: Education, Prevention, and Policy* **5**: 257-67.
63. Ward J, Henderson Z & Pearson G (2003) *Home Office Research Study 260. One problem among many: drug use among care leavers in transition to independent living*. London: Home Office Research, Development and Statistics Directorate.
64. Newburn T & Person G (2002) *The place and meaning of drug use in the lives of young people in care*. London: University College London.
65. Lynskey MT, Heath AC, Bucholz KK et al (2003) Escalation of drug use in early-onset cannabis users vs co-twin controls. *The Journal of the American Medical Association* **289**: 427-33.
66. Meier PS, Donmall MC & McElduff P (2004) Characteristics of drug users who do or do not have care of their children. *Addiction* **99**: 955-61
67. Cusick L, Martin A & May T (2003) *Home Office Research Study 268. Vulnerability and involvement in drug use and sex work*. London: Home Office Research, Development and Statistics Directorate.
68. Rugg J (2000) *Making connections: tackling youth homelessness through a multi-agency approach*. London: Shelter.
69. Fountain J, Howes S, Marsden J et al (2003) Drug and alcohol use and the link with homelessness: results from a survey of homeless people in London. *Addiction Research and Theory* **11**: 245-56.

70. Wincup E, Buckland G & Bayliss R (2003) *Home Office Research Study 258. Youth homelessness and substance use: report to the drugs and alcohol research unit*. London: Home Office Research, Development and Statistics Directorate.
71. Gordon HW (2002) Early environmental stress and biological vulnerability to drug abuse. *Psychoneuroendocrinology* **27**: 115-26.
72. World Health Organization (2009) *Interpersonal violence and illicit drugs*. Geneva: World Health Organization.
73. Widom CS, Marmorstein NR & White HR (2006) Childhood victimization and illicit drug use in middle adulthood. *Psychology of Addictive Behaviors* **20**: 394-403.
74. Harrison PA, Fulkerson JA & Beebe TJ (1997) Multiple substance use among adolescent physical and sexual abuse victims. *Child Abuse and Neglect* **21**: 529-39
75. Moran PB, Vuchinich S & Hall NK (2004) Associations between types of maltreatment and substance use during adolescence. *Child Abuse and Neglect* **28**: 565-74
76. Spertus IL, Yehuda R, Wong CM et al (2003) Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice. *Child Abuse and Neglect* **27**: 1247-58
77. Paula RL, Kilmer B & Hunt P (2010) A framework for thinking about the drugs market. In: Kimler B & Hoorens S (eds) *Understanding illicit drug markets, supply-reduction efforts, and drug-related crime in the European Union*. Santa Monica: Rand Europe.
78. Pacula RL, Grossman M, Chaloupka FJ et al (2001) *Risky behaviours among youths: an economic analysis*. Chicago, IL: University of Chicago Press.
79. Cameron L & Williams J (2001) Cannabis, alcohol and cigarettes: substitutes or complements? *Economic Record* **77**: 19-34.
80. Chaloupka FJ, Grossman M, Bickel WK et al (1999) *The economic analysis of substance use and abuse: an integration of econometric and behavioural economic research*. Chicago, IL: Chicago University Press.
81. Williams J, Pacula RL, Chaloupka FJ et al (2006) College students' use of cocaine. *Substance Use and Misuse* **41**: 489-509.
82. Office of National Drug Control Policy (2011) *National drug control strategy: data supplement 2011*. Washington DC: Office of National Drug Control Policy.
83. Bretteville-Jensen A (2006) Drug demand – initiation, continuation and quitting. *De Economist* **154**: 491-516.
84. Dave D (2008) Illicit drug use among arrestees, prices and policy. *Journal of Urban Economics* **3**: 694-714.
85. Dave D (2006) The effects of cocaine and heroin price on drug-related emergency department visits. *Journal of Health Economics* **25**: 311-33.
86. Freisthler B, LaScala EA, Gruenewald PJ et al (2005) An examination of drug activity: effects of neighborhood social organization on the development of drug distribution systems, *Substance Use and Misuse* **40**: 671-86
87. Saxe L, Kadushin C, Beveridge A et al (2001) The visibility of illicit drugs: implications for community-based drug control strategies, *American Journal of Public Health* **91**: 1987-94.
88. British Medical Association (2008) *Forever cool: the influence of smoking imagery on young people*. London: British Medical Association.
89. Anderson P, de Bruijn A, Angus K et al (2009) Impact of alcohol advertising and media exposure on adolescent alcohol use: a systematic review of longitudinal studies. *Alcohol and Alcoholism* **44**: 229-43.
90. School of Health and Related Research University of Sheffield (2008) *independent review of the effects of alcohol pricing and promotion. Part A: systematic reviews*. Sheffield: School of Health and Related Research, University of Sheffield.
91. Smith L & Foxcroft D (2009) The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies. *BMC Public Health* **9**: 51.
92. Hunt K, Sweeting H, Sargent J et al (2011) Is there an association between seeing incidents of alcohol or drug use in films and young Scottish adults' own alcohol or drug use? A cross sectional study. *BMC Public Health* **11**: 259.
93. Primack BA, Douglas EL & Kraemer KL (2010) Exposure to cannabis in popular music and cannabis use among adolescents. *Addiction* **105**: 515-23.

94. Brown WJ & de Matviuk (2010) Sports celebrities and public health: Diego Maradona's influence on drug use prevention. *Journal of Health Communication* **15**: 358-73.
95. Padilla-Walker L, Nelson L, Carroll J et al (2010) More than a just a game: video game and internet use during emerging adulthood. *Journal of Youth and Adolescence* **39**: 103-13.
96. Belenko S, Dugosh KL, Lynch K et al (2009) Online illegal drug use information: an exploratory analysis of drug-related website viewing by adolescents. *Journal of Health Communication* **14**: 612-30.
97. Hornik R, Maklan D, Cadell D et al (2006) *Evaluation of the national youth antidrug media campaign: 2004 report of findings*. Washington DC: National Institute on Drug Abuse.
98. Slater MD, Kelly KJ, Edwards RW et al. (2006) Combining in-school and community-based media efforts: reducing marijuana and alcohol uptake among younger adolescents. *Health Education Research* **21**: 157-67.
99. Stern SR (2005) Messages from teens on the big screen: smoking, drinking, and drug use in teen-centered films. *Journal of Health Communication* **10**: 331-46.
100. Gunasekera H, Chapman S & Campbell S (2005) Sex and drugs in popular movies: an analysis of the top 200 films. *Journal of the Royal Society of Medicine* **98**: 464-70.
101. British Medical Association (2009) *Under the influence: the damaging effect of alcohol marketing on young people*. London: British Medical Association.
102. Cumberbatch G & Gauntlett S (2005) *Smoking, alcohol and drugs on television: a content analysis*. London: Ofcom.
103. Took KJ & Weiss DS (1994) The relationship between heavy metal and rap music and adolescent turmoil: real or artifact? *Adolescence* **29**: 613-21.
104. Mark A (1986) Adolescents discuss themselves and drugs through music. *Journal of Substance Treatment* **3**: 243-9.
105. Keen AW (2005) Using music as a therapy tool to motivate troubled adolescents. *Social Work in Health Care* **39**: 361-73.
106. Primack BA, Dalton MA, Carroll MV et al (2008) Content analysis of tobacco, alcohol, and other drugs in popular music. *Archives of Pediatrics and Adolescent Medicine* **162**: 169-75.
107. United Nations International Narcotics Control Board (2008) *Report of the International Narcotics Control Board for 2007*. Vienna: United Nations International Narcotics Control Board.
108. Boon SD & Lomore CD (2001) Admirer-celebrity relationships among young adults. *Human Communication Research* **27**: 432-65.
109. Thompson KM, Tepichin K & Haninger K (2006) Content and ratings of mature-rated video games. *Archives of Pediatrics and Adolescent Medicine* **160**: 402-10.
110. Haninger K & Thompson KM (2004) Content and ratings of teen-rated video games. *The Journal of the American Medical Association* **291**: 856-65.

Chapter 5

1. Berridge V (1978) Victorian opium eating. *Victorian Studies* **21**: 437-61.
2. Berridge V (1984) Drugs and social policy: the establishment of drug control in Britain 1900-1930. *British Journal of Addiction* **79**: 17-29.
3. Ministry of Health (1926) *Report of the Departmental Committee on Morphine and Heroin Addiction (The Rolleston Report)*. London: Her Majesty's Stationery Office.
4. Interdepartmental Committee (1961) *Drug addiction (The Brain Report)*. London: Her Majesty's Stationery Office.
5. Ministry of Health and Scottish Home and Health Department (1965) *Drug addiction: the second report of the Interdepartmental Committee (The Second Brain Report)*. London: Her Majesty's Stationery Office.
6. Smart C (1985) Social policy and drug dependence: an historical case study. *Drug and Alcohol Dependence* **16**: 169-80.
7. Stimson GV & Oppenheimer E (1982) *Heroin addiction: treatment and control in Britain*. London: Tavistock.
8. Advisory Committee on Drug Dependence (1968) *Cannabis (The Wootton Report)*. London: Her Majesty's Stationery Office.
9. www.unodc.org/unodc/en/treaties/single-convention.html (accessed 2 October 2012)
10. www.legislation.gov.uk/ukpga/1971/38/contents (accessed 2 October 2012)

11. Home Office (1985) *Tackling drug misuse*. London: Her Majesty's Stationery Office.
12. Advisory Council on the Misuse of Drugs (1982) *Treatment and rehabilitation*. London: Her Majesty's Stationery Office.
13. Medical Working Group on Drug Dependence (1984) *Guidelines of good clinical practice in the treatment of drug misuse*. London: Department of Health and Social Security.
14. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive (2007) *Drug misuse and dependence. UK guidelines on clinical management*. London: Department of Health.
15. Advisory Council on the Misuse of Drugs (1988) *AIDS and drug misuse. Part 1*. London: Her Majesty's Stationery Office.
16. Advisory Council on the Misuse of Drugs (1989) *AIDS and drug misuse. Part 2*. London: Her Majesty's Stationery Office.
17. Stimson GV (1995) AIDS and injecting drug use in the United Kingdom, 1987-1993: the policy response and the prevention of epidemic. *Social Science and Medicine* **41**: 699-716.
18. Gruer L, Wilson P, Scott P et al (1997) General practitioner centred scheme for treatment of opiate dependents in Glasgow. *British Medical Journal* **314**: 1730-5.
19. Home Office (1998) *Statistics of drug seizures and offenders dealt with, United Kingdom, 1996*. London: Home Office.
20. Her Majesty's Government (1995) *Tackling drugs together: a strategy for England 1995-1998* (Cmd 2846). London: Her Majesty's Stationery Office.
21. The Task Force to Review Services for Drug Misusers (1996) *Report of an independent review of drug treatment services in England*. London: Department of Health.
22. Home Office (1998) *Tackling drugs to build a better Britain*. London: Her Majesty's Stationery Office.
23. Reuter P & Stevens A (2007) *An analysis of UK drug policy*. London: UK Drug Policy Commission.
24. Budd T, Collier P, Mhlanga B et al (2005) *Levels of self-report offending and drug use among offenders: findings from the Criminality Surveys*. London: Home Office.
25. UK Drug Policy Commission (2008) *Reducing drug use, reducing reoffending. Are programmes for problem drug-using offenders in the UK supported by the evidence?* London: UK Drug Policy Commission.
26. Home Office Drugs Strategy Directorate (2002) *Updated drug strategy*. London: Home Office Drugs Strategy Directorate.
27. Home Office Drug Strategy Directorate (2004) *Tackling drugs: changing lives*. London: Home Office Drugs Strategy Directorate.
28. Her Majesty's Government (2008) *Drugs: protecting families and communities. The 2008 drug strategy*. London: Home Office.
29. MacGregor S (2010) Policy responses to the drugs problem. In: MacGregor S (ed) *Responding to drug misuse*. Hove: Routledge.
30. Her Majesty's Government (2010) *Drug strategy 2010. Reducing demand, restricting supply, building recovery: supporting people to lead a drug free life*. London: Her Majesty's Government.
31. Home Office (2012) *Putting full recovery first*. London: Home Office.

Chapter 6

1. Weatherburn D, Topp L, Midford R et al (2000) *Drug crime prevention and mitigation: a literature review and research agenda*. Sydney: New South Wales Bureau of Crime Statistics and Research.
2. Manski CF, Pepper JV & Petrie CV (eds) (2001) *Informing America's policy on illegal drugs: what we don't know keeps hurting us*. Washington DC: National Academy Press.
3. House of Commons Science and Technology Select Committee *Drug classification: making a hash of it: fifth report of session 2005-2006*. HC 1031. 2005-6.
4. Her Majesty's Government (2006) *The Government reply to the 5th Report from the House of Commons science and technology committee session 2005-06 HC1031*. London: Her Majesty's Stationery Office.
5. Dölling D, Entorf H, Hermann D et al (2009) Is deterrence effective? Results of a meta-analysis of punishment. *European Journal on Criminal Policy and Research* **15**: 201-24.
6. The Police Foundation (1999) *Drugs and the law: report of the independent inquiry into the Misuse of Drugs Act 1971 (The Runciman Report)*. London: The Police Foundation.

7. Kleinman (2009) *When brute force fails: how to have less crime and less punishment*. Princeton, NJ: Princeton University Press.
8. Babor T, Caulkins J, Edwards G et al (2010) *Drug policy and the public good*. Oxford: Oxford University Press.
9. Degenhard L, Chiu WT, Sampson N et al (2008) Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. *PLoS Medicine* **5**: e141.
10. Nutt DJ, King LA & Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. *The Lancet* **376**: 1558-65.
11. van Amsterdam JGC, Opperhuizen A, Koeter M et al (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. *European Addiction Research* **16**: 202-27.
12. Room R (2012) Reform by subtraction: the path of denunciation of international drug treaties and reaccession with reservations. *International Journal of Drug Policy* **23**: 401-06.
13. Stevens A (2011) *Drugs crime and public health: the political economy of drug policy*. London: Routledge.
14. House of Commons Home Affairs Select Committee *The government's drugs policy: is it working?* HC 381 (Memorandum 73 – Home Office), 2001-2.
15. Meacham M, Zobel F, Hughes B et al (2010) *Review of methodologies of evaluating effects of drug-related legal changes*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
16. Advisory Council on the Misuse of Drugs (2006) *Pathways to problems. Hazardous use of tobacco, alcohol and other drugs by young people in the UK and its implications for policy*. London: Central Office of Information.
17. Jarvik ME (1990) The drug dilemma: manipulating the demand. *Science* **250**: 387-92.
18. Her Majesty's Government (1998) *Tackling drugs to build a better Britain*. London: The Stationery Office.
19. Home Office Drugs Strategy Directorate (2002) *Updated drug strategy 2002*. London: Home Office.
20. Her Majesty's Government (2010) *Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live a drug free life*. London: Her Majesty's Government.
21. Daly M (2009) Commercial breakdown. *Druglink* **24**: 4-11.
22. Tree S (2003) The war at home. *Sojourners* May/June.
23. Kilmer B & Reuter P (2009) Prime numbers: doped. *Foreign Policy* **November/December**: 34-5.
24. Prime Minister's Strategy Unit (2003) *Strategy Unit drugs report. Phase one – understanding the issues*. London: Prime Minister's Strategy Unit.
25. Grossman M (2004) *Individual behaviours and substance use: the role of price*. NBER working paper 10948. Cambridge, MA: National Bureau of Economic Research.
26. Aldridge J, Measham F & Williams L (2011) *Illegal leisure revisited*. London: Routledge.
27. Bush W, Roberts M & Trace M (2004) *Upheavals in the Australian drug market: heroin drought, stimulant flood. A DrugScope briefing paper for the Beckley Foundation Drug Policy Programme*. Oxford: Beckley Foundation.
28. Wood E, Stoltz JA, Li K et al (2006) Changes in Canadian heroin supply coinciding with the Australian heroin shortage. *Addiction* **101**: 689-95.
29. Executive Director of the United Nations Office on Drugs and Crime (2008) *Making drug control 'fit for purpose': building on the UNGASS decade. Report by the executive director of the united nations office on drugs and crime as a contribution to the review of the twentieth special session of the General Assembly*. Fifty-first Session Commission on Narcotic Drugs, 10-14 March, Vienna, Austria.
30. www.countthecosts.org (accessed 2 October 2012).
31. Jones L, Bates G, Bellis M et al (2011) *A summary of the health harms of drugs*. London: Department of Health.
32. Cole C, Jones L, McVeigh J et al (2010) *CUT: a guide to adulterants, bulking agents and other contaminants found in illicit drugs*. Liverpool: Centre for Public Health, Liverpool John Moores University.
33. Ben Lakhdar C & Bastianic T (2011) Economic constraint and modes of consumption of addictive goods. *International Journal of Drug Policy* **22**: 360-5.
34. Levine HG & Reinerman C (2004) Effects of prohibition on consumption and public health. In: *Alcohol prohibition and drug prohibition. Lessons from alcohol policy for drug policy*. Amsterdam: Centre for Drug Research.
35. Rhodes T, Singer M, Bourgois P et al (2005) The social structural production of HIV risk among injecting

- drug users. *Social Science and Medicine* **61**: 1026-44.
36. Kerr T, Small W & Wood E (2005) The public health and social impacts of drug market enforcement: a review of the evidence. *International Journal of Drug Policy* **16**: 210-20.
 37. Csete J (2010) *From the mountaintops: what the world can learn from drug policy change in Switzerland*. New York: Open Society Foundations.
 38. Pudney S, Badillo C, Bryan M et al (2006) Estimating the size of the UK illicit drug market. In: Singleton M, Murray R & Tinsley L (eds) *Measuring different aspects of problem drug use: methodological developments*. Home Office online Report (www.homeoffice.gov.uk, accessed 2 October 2012).
 39. United Nations Office on Drugs and Crime (2005) *2005 World drug report. Volume 1: analysis*. Vienna: United Nations Office on Drugs and Crime.
 40. Werb D, Rowell G, Guyatt G et al (2011) Effect of drug law enforcement on drug market violence: a systematic review. *International Journal of Drug Policy* **22**: 87-94.
 41. United Nations Office on Drugs and Crime (2011) *Estimating illicit financial flows resulting from drug trafficking and other transnational organized crimes*. Vienna: United Nations Office on Drugs and Crime.
 42. United Nations Office on Drugs and Crime (2010) *The globalization of crime. A transnational organized crime threat assessment*. Vienna: United Nations Office on Drugs and Crime.
 43. Stevens A (2008) Weighing up crime: the overestimation of drug-related crime. *Journal of Contemporary Drug Problems* **35**: 265-90.
 44. Home Office Statistical Bulletin (2007) *The arrestee survey 2003-2006*. London: Home Office.
 45. Department of Health, Home Office, Department for Education and Skills and Department for Culture, Media and Sport (2007) *Safe. Sensible. Social. The next steps in the national alcohol strategy*. London: Her Majesty's Government.
 46. British Medical Association (2008) *Alcohol misuse: tackling the UK epidemic*. London: British Medical Association.
 47. Department of Health (2010) *A smokefree future: a comprehensive tobacco control strategy for England*. London: Her Majesty's Government.
 48. Lines R (2010) Deliver us from evil? The single convention on narcotic drugs, 50 years on. *International Journal of Human Rights and Drug Policy* **1**: 1-13.
 49. Human Rights Watch publications and other resources (www.hrw.org, accessed 2 October 2012).
 50. Human Rights Watch (2010) *Human rights and drug policy briefing 5: controlled essential medicines*. New York, NY: Human Rights Watch.
 51. World Health Organization (2011) *Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicines*. Geneva: World Health Organization.
 52. UK Harm Reduction Alliance (2002) *Response of the UK Harm Reduction Alliance to the Hepatitis C Strategy for England*. Dorset: UK Harm Reduction Alliance.
 53. Barrett D, Lines R, Schliefer R et al (2008) *Recalibrating the regime: the need for a human rights based approach to international drug policy*. Oxford: Beckley Foundation Drug Policy Programme and International Harm Reduction Association.
 54. Lister S, Seddon T, Wincup E et al (2008) *Street policing of problem drug users*. York: Joseph Rowntree Foundation.
 55. Ahern J, Stuber J & Galea S (2007) Stigma, discrimination and the health of illicit drug users. *Drug and Alcohol Dependence* **88**: 188-96.
 56. Levine HG, Peterson & Small H (2008) *Marijuana arrest crusade. Racial bias and police policy in New York City*. New York: New York Civil Liberties Union.
 57. Levine HG, Gettman JB & Siegel JD (2010) *Arresting blacks for marijuana in California. Possession arrests in 25 cities, 2006-08*. Los Angeles/Sacramento: Drug Policy Alliance and the California State Conference of the National Association for the Advancement of Colored People.
 58. AlterNet (22.7.12) *It's not just NYC: across America, only black and brown people get arrested for pot*.
 59. Miller J (2010) Stop and search in England: a reformed tactic or business as usual? *British Journal of Criminology* **50**: 954-74.
 60. United Nations Office on Drugs and Crime (2010) *World drug report 2010*. Vienna: United Nations Office on Drugs and Crime.
 61. Inkster N & Comolli V (2012) *Drugs, insecurity and failed states: the problems of prohibition*. London: Routledge.
 62. Keefer P & Loayza N (eds) (2010) *Innocent bystanders: developing countries and the war on drugs*.

- Washington: World Bank and Palgrave Macmillan.
63. Davies C (2011) Drug policy: legislation, strategies and economic analysis. In: *United Kingdom drug situation: UK focal point on drugs. Annual report to the european monitoring centre for drugs and drugs of addiction (EMCDDA) 2011*. London: Department of Health.
 64. Home Office (2007) *Drugs value for money review. July 2007 Report*. London: Home Office.
 65. Gordon L, Tinsley L, Godfrey C et al (2006) The economic and social costs of Class A drug use in England and Wales, 2003/04. In: Singleton M, Murray R & Tinsley L (eds) *Measuring different aspects of problem drug use: methodological developments*. Home Office online Report 16/06 (www.homeoffice.gov.uk, accessed 2 October 2012).
 66. McKeganey N (2010) *Controversies in drug policy and practice*. Basingstoke: Palgrave Macmillan.
 67. The International Task Force on Strategic Policy (2011) *Drug legalisation: an evaluation of the impacts on global society. Position statement December 2011* (www.itfsdp.org, accessed 2 October 2012).
 68. World Federation Against Drugs (2011) *Global commission on drug policy offers inaccurate, reckless, vague drug legalization proposal*. Stockholm: World Federation Against Drugs.
 69. Costa A (2009) *World drug report 2009*. Vienna: United Nations Office on Drugs and Crime.
 70. United Nations Office on Drugs and Crime (1997) *World drug report 1997*. Vienna: United Nations Office on Drugs and Crime.
 71. US Drug Enforcement Administration (2010) *Speaking out against drug legalization*. Springfield: Drug Enforcement Administration.
 72. Advisory Council on the Misuse of Drugs (2010) *2010 Drug strategy consultation. Responses from the Advisory Council on the Misuse of Drugs to questions for consultation*. London: Advisory Council on the Misuse of Drugs.
 73. The Guardian (14.10.12) *Home Office rejects decriminalising possession of drugs for personal use*.
 74. *Real Commission on Drug Policy (2011) War on drugs. Report of the Real Commission on Drug Policy*. Rio de Janeiro: Real Commission on Drug Policy.
 75. Hansard (2012) 16 Jan 2012 Column WA114: *Written Parliamentary answer to The Earl of Dundee from the The Minister of State, Home Office (Lord Henley)*.
 76. Bean P (2010) *Legalising drugs: debates and dilemmas*. Bristol: Policy Press.
 77. House of Commons Home Affairs Select Committee *The government's drugs policy: is it working?* HC 381, 2001-2.
 78. RSA Commission on Illegal Drugs, Communities and Public Policy (2007) *Drugs – facing facts. The report of the RSA commission on illegal drugs, communities and public policy*. London: The Royal Society for the Encouragement of Arts, Manufactures and Commerce.
 79. Reuter P & Stevens A (2007) *An analysis of UK drug policy*. London: UK Drug Policy Commission.
 80. Wood E, Werb D, Kazatchkine M et al (2010) Vienna declaration: a call for evidence-based drug policies. *The Lancet* **376**: 310-2.
 81. UK Drug Policy Commission (2012) *A fresh approach to drugs*. London: UK Drug Policy Commission.
 82. MacCoun RJ & Reuter P (2001) *Drug war heresies: learning from other vices, times, and places*. Cambridge: Cambridge University Press.
 83. Rolles S (2009) *After the war on drugs: blueprint for regulation*. Bristol: Transform Drug Policy Foundation.
 84. The Wall Street Journal (14.05.09) *White house czar calls for end to 'war on drugs'*.
 85. Social Justice Policy Group (2007) *Breakthrough Britain: addictions*. London: The Centre for Social Justice.
 86. The Sentencing Council (2011) *Drug offences guideline. Public consultation*. London: The Sentencing Council.
 87. Rosmarin A & Eastwood N (2012) *A quiet revolution: drug decriminalisation policies in practice across the globe*. London: Release.
 88. European Monitoring Centre for Drugs and Drug Addiction (2011) Policies and laws. National legislation. Personal possession of drugs: ten years of penalty changes in Europe. In: *Annual report 2011. The state of the drugs problem in Europe*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
 89. European Monitoring Centre for Drugs and Drug Addiction (2011) *Annual report 2011. The state of the drugs problem in Europe*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

90. Harris G (2011) *TNI/EMCDDA expert seminar on threshold quantities*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
91. European Monitoring Center for Drugs and Drug Addiction (2001) *European legal database on drugs*. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
92. www.druglawreform.info/en/country-information/drug-law-reform-on-the-map (accessed 2 October 2012).
93. Pachico E (2011) *Colombia takes step towards drug decriminalization*. Washington: InSightCrime.
94. United Nations Office on Drugs and Crime (2010) *Accessibility of HIV prevention, treatment and care services for people who use drugs and incarcerated people in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan: legislative and policy analysis and recommendations for reform*. Uzbekistan: United Nations Office on Drugs and Crime, Regional Office for Central Asia.
95. Greenwald G (2009) *Drug decriminalization in Portugal: lessons for creating fair and successful drug policies*. Washington: CATO Institute.
96. Hughes CE & Stevens A (2012) A resounding success or a disastrous failure: re-examining the interpretation of evidence on the Portuguese decriminalisation of illicit drugs. *Drug and Alcohol Review* **31**: 101-13.
97. Pinto Coelho M (2010). *The 'resounding success' of Portuguese drug policy. The power of an attractive fallacy*. Cascais: Association for a Drug Free Portugal.
98. Hughes C & Stevens A (2010) What can we learn from the Portuguese decriminalization of illicit drugs? *British Journal of Criminology* **50**: 999-1022.
99. European Monitoring Centre for Drugs and Drug Policy (2011) *Drug policy profiles – Portugal*. Luxembourg: European Monitoring Centre for Drugs and Drug Policy.
100. Nadelmann EA (1992) Thinking seriously about alternatives to drug prohibition. *Daedalus* **121**: 85-132.
101. World Health Organization (2011) *WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco*. Geneva: World Health Organization.
102. King County Bar Association Drug Policy Project (2005) *Effective drug control: toward a new legal framework. State-level intervention as a workable alternative to the 'war on drugs'*. Seattle: King County Bar Association.
103. Health Officers Council of British Columbia (2005) *A public health approach to drug control*. Victoria: Health Officers Council of British Columbia.
104. The Health Officers Council of British Columbia (2011) *Public health perspectives for regulating psychoactive substances: what we can do about alcohol, tobacco, and other drugs*. Vancouver: Health Officers Council of British Columbia.
105. Rolles S (2010) An alternative to the war on drugs. *British Medical Journal* **341**: c3360.
106. Grover A (2010) *Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health (Item 69(b) of the provisional agenda of the sixty-fifth session of the United Nations General Assembly)*. New York: United Nations.
107. World Health Organization (2003). *WHO framework convention on tobacco control*. Geneva: World Health Organization.
108. Addaction press release (18.10.10) *Addaction responds to the government's drug strategy consultation*.
109. Select Committee on Home Affairs *Memorandum submitted by Turning Point*. Appendices to the Minutes of Evidence, Appendix 12, 2001-2.
110. Westminster Drug Project (2010) *WDP (Westminster Drug Project) response to the Home Office consultation on the government's 2010 Drug Strategy*. London: Westminster Drug Project.
111. House of Commons Home Affairs Select Committee *The government's drugs policy: is it working?* HC 381 (Memorandum 20 – DrugScope), 2001-2.
112. DrugScope (2011) *DrugScope responds to global commission on drug policy report*. London: DrugScope.
113. DrugScope (2010) *The 2010 drug strategy consultation. Response from DrugScope*. London: DrugScope.
114. Harm Reduction International (2011) *HIV and injecting drug use: a global call for action. The Official Declaration of the 2011 International Harm Reduction Conference*. London: Harm Reduction International.

Chapter 7

1. Babor T, Caulkins JP, Edwards G et al (2010) *Drug policy and the public good*. Oxford: Oxford University Press.
2. Neighbors C, Larimer E, Lostutter TW et al (2006) Harm reduction and individually focused alcohol prevention. *International Journal of Drug Policy* **17**: 304-9.
3. UK Drug Policy Commission (2007) *An analysis of UK drug policy: a monograph prepared for the UK drug policy commission*. London: UK Drug Policy Commission.
4. Advisory Council on the Misuse of Drugs (2006) *Pathways to problems*. London: Advisory Council on the Misuse of Drugs.
5. Yamaguchi K & Kandel DB (1984) Patterns of drug use from adolescence to young adulthood: . Predictors of progression. *American Journal of Public Health* **74**: 673-81.
6. Lynskey MT, Heath AC, Bucholz KK et al (2003) Escalation of drug use in early-onset cannabis users vs co-twin controls. *The Journal of the American Medical Association* **289**: 427-33.
7. Fergusson DM, Boden JM & Horwood LJ (2006) Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. *Addiction* **101**: 556-69.
8. Midford R (2000) Does drug education work? *Drug and Alcohol Review* **19**: 441-6.
9. Caulkins JP, Rydell CP, Everingham SS et al (1999) *An ounce of prevention a pound of uncertainty*. Santa Monica, CA: Rand.
10. The Advisory Group on Drug and Alcohol Education (2008) *Drug education: an entitlement for all a report to government by the advisory group on drug and alcohol education*. London: The Advisory Group on Drug and Alcohol Education.
11. Faggiano F, Vigna-Taglianti F, Versino E et al (2005) School-based prevention for illicit drugs use. *Cochrane Database of Systematic Reviews* (2): CD003020.
12. Botvin GJ, Baker E, Dusenbury L et al (1995) Long-term follow-up results of a randomized drug abuse prevention trial in a white middle-class population. *The Journal of the American Medical Association* **273**: 1106-12.
13. Kellam SG, Brown CH, Poduska JM et al (2008) Effects of a universal classroom behaviour management program in first and second grades on young adult behavioural, psychiatric and management outcomes. *Drug and Alcohol Dependence* **95**: S5-S28
14. Department for Education and Skills (2004) *Drugs: guidance for schools*. London: Department for Education and Skills.
15. Department for Education & Association of Chief Police Officers (2012) *DfE and ACPO drug advice for schools*. London: Department for Education.
16. Ofsted (2005) *Drug education in schools*. Manchester: Ofsted.
17. Lloyd C, Joyce R, Hurry J et al (2000) The effectiveness of primary school drug education. *Drugs: Education, Prevention, and Policy* **7**: 109-26.
18. The NHS Information Centre (2011) *Statistics on drug misuse: England 2010*. London: The NHS Information Centre.
19. Home Office (2009) *Blueprint drugs education: the response of pupils and parents to the programme – executive summary*. London: Home Office.
20. The NHS Information Centre (2011) *Smoking, drinking and drug use among young people in England in 2011*. London: The NHS Information Centre.
21. Yamaguchi R, Jonston LD & O'Malley PM (2003) *Drug testing in schools: policies, practices, and association with student drug use*. Ann Arbor, Michigan: University of Michigan.
22. Joseph Rowntree Foundation (2005) *Random drug testing of school children: a shot in the arm or a shot in the foot for drug prevention*. York: Joseph Rowntree Foundation.
23. Gates S, McCambridge J, Smith LA et al (2006) Interventions for prevention of drug use by young people delivered in non-school settings. *Cochrane Database of Systematic Reviews* (1): CD005030.
24. www.talktofrank.com (accessed 3 October 2012).
25. Her Majesty's Government (2010) *Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live a drug free life*. London: Her Majesty's Government.
26. World Health Organization (2002) *Prevention of psychoactive substance use*. Geneva: World Health Organization.

27. National Institute on Drug Abuse (2006) *Evaluation of the national youth antidrug media campaign: 2004 report of findings*. Washington DC: National Institute on Drug Abuse.
28. Slater MD, Kelly KJ, Edwards RW et al (2006) Combining in-school and community-based media efforts: reducing marijuana and alcohol uptake among younger adolescents. *Health Education Research* **21**: 157-67.
29. Lloyd C (1998) Risk factors for problem drug use: Identifying vulnerable groups. *Drugs Education, Prevention and Policy* **5**: 217-32.
30. Smyth NJ & Saulnier CF (1996) Substance abuse prevention among high-risk youth. *Journal of Prevention and Intervention in the Community* **14**: 61-79.
31. National Institute for Health and Clinical Excellence (2006) *Drug use prevention among young people: a review of reviews*. London: National Institute for Health and Clinical Excellence.
32. Roe S, Becker J (2005) Drug prevention with vulnerable young people: a review. *Drugs: Education, Prevention, and Policy* **12**: 85-99.
33. Department of Health (2000) *Vulnerable young people and drugs: opportunities to tackle inequalities*. London: Department of Health.
34. Hammersley R, Marsland L & Reid M (2003) *Substance use by young offenders: the impact of the normalisation of drug use in the early years of the 21st century*. Home Office Research Study 261. London: Home Office Research Development and Statistics Directorate.

Chapter 8

1. World Health Organization/United Nations Office of Drugs and Crime/Joint United Nations Programme on HIV/AIDS (2004) *WHO/UNODC/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention*. Geneva: World Health Organization.
2. Newman RG (1983) The need to redefine 'addiction'. *New England Journal of Medicine* **308**: 1096-8.
3. McLellan AT, McKay JR, Forman R et al. (2005) Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. *Addiction* **100**: 447-58.
4. Fishbein M, Hall-Jamieson K, Zimmer E et al (2002) Avoiding the boomerang: testing the relative effectiveness of antidrug public service announcements before a national campaign. *American Journal of Public Health* **92**: 238-45.
5. House of Commons Home Affairs Select Committee *The government's drugs policy: is it working?* HC 381, 2001-2.
6. Gyngell K (2011) *Breaking the habit*. London: Centre for Policy Studies.
7. Ball JC & Ross A (1991) *The effectiveness of methadone maintenance treatment: patients, programs, services and outcome*. New York: Springer-Verlag.
8. Dole VP & Nyswander M (1973) *Rehabilitation of patients on methadone programs*. Proceedings of the 5th National Conference on Methadone Treatment, 17-19 March, Washington DC.
9. Rosenbaum M (1995) The demedicalization of methadone maintenance. *Journal of Psychoactive Drugs* **27**: 145-9.
10. D'Aunno T & Vaughan TE (1992) Variations in methadone treatment practices: Results from a national study. *Journal of the American Medical Association* **267**: 253-8.
11. Leshner AI (1997) Addiction is a brain disease and it matters. *Science* **278**: 45-7.
12. Jaffe J & O'Keefe C (2003) From morphine clinics to buprenorphine; regulating opioid antagonist treatment of addiction in the United States. *Drug and Alcohol Dependence* **70**: S3-S11.
13. Strang J, Metrebian N, Lintzeris N et al (2010) Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. *The Lancet* **375**: 1885-95.
14. Oviedo-Joekes E, Brissette S, Marsh DC et al (2009) Diacetylmorphine versus methadone for the treatment of opioid addiction. *New England Journal of Medicine* **361**: 777-86.
15. Haasen C, Verthein U & Degkwitz P (2007) Heroin-assisted treatment for opioid dependence: randomised controlled trial. *British Journal of Psychiatry* **191**: 55-62.
16. Stimson GV (1995) AIDS and injecting drug use in the UK: the policy response and the prevention of the epidemic. *Social Science and Medicine* **41**: 699-716.
17. National Institute for Health and Clinical Excellence (2007) *Methadone and buprenorphine for the management of opioid dependence*. *Technology Appraisal Guidance* 114. London: National Institute for Health and Clinical Excellence.

18. Her Majesty's Government (2010) *Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live a drug free life*. London: Her Majesty's Government.
19. Hser YI, Hoffman V, Grella CE et al (2001) A 33-year follow-up of narcotics addicts. *Archives of General Psychiatry* **58**: 503-08.
20. Haastруп S & Jepsen PW (1988). Eleven year follow-up of 300 young opioid addicts. *Acta Psychiatrica Scandinavica* **77**: 22-6.
21. Vaillant GE (1988) What can long-term follow-up teach us about relapse and prevention of relapse in addiction? *British Journal of Addiction* **83**: 1147-57.
22. Robins L (1993) Vietnam veterans rapid recovery from heroin addiction: a fluke, or normal expectation? *Addiction* **88**: 1041-54.
23. Dawson DA (1996) Correlates of past-year status among treated and untreated persons with former alcohol dependence: United States, 1992. *Alcoholism, Clinical and Experimental Research* **20**: 771-9.
24. Milby JB (1988). Methadone maintenance to abstinence: how many make it? *Journal of Nervous and Mental Disease* **176**: 409-22.
25. Recovery Orientated Drug Treatment Group, National Treatment Agency for Substance Misuse (2012) *Medications in recovery. Re-orientating drug dependence treatment*. London: National Treatment Agency for Substance Misuse.
26. Kimber J, Copeland L, Hickman M et al. (2010) Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. *British Medical Journal* **340**: c3172.
27. Hubbard R, Marsden M, Rachel J et al (1989) *Drug abuse treatment: a national study of effectiveness*. Chapel Hill: The University of North Carolina Press.
28. Gossop M, Marsden J, Stewart D et al (2002) The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. *Addiction* **98**: 291-303.
29. Teesson M, Mills K, Ross J et al (2007) The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). *Addiction* **103**: 80-8.
30. Gossop M, Marsden J & Stewart D (2001) *NTORS after five years (National Treatment Outcome Research Study): changes in substance use, health and criminal behaviour during the five years after intake*. London: National Addiction Centre.
31. Godfrey C, Stewart D & Gossop M (2004) Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). *Addiction* **99**: 697-707.
32. Clausen T, Anchersen K & Waal H (2008) Mortality prior to, during and after opioid maintenance treatment (OMT); a national, prospective cross-registry study. *Drug and Alcohol Dependence* **94**: 151-7.
33. Bell J, Dru A, Fischer B et al (2002) Substitution therapy for heroin addiction *Substance Use and Misuse* **37**: 1145-74.
34. Romelsjö A, Engdahl B, Stenbacka M et al (2010) Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? *Addiction* **105**: 1625-32.
35. Turner KM, Hutchinson S, Vickerman P et al (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence *Addiction* **106**: 1978-88.
36. Wodak A & Cooney A (2006) Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. *Substance Use and Misuse* **41**: 777-813.
37. De Maeyer J, Vanderplasschen W & Broekaert E (2010) Quality of life among opiate-dependent individuals: a review of the literature. *International Journal of Drug Policy* **21**: 364-80.
38. Reno RR & Aiken LS (1993) Life activities and life quality of heroin addicts in and out of methadone treatment. *International Journal of the Addictions* **28**: 211-32.
39. Bell J, Mattick RP, Chan J et al (1997) Methadone maintenance and drug related crime. *Journal of Substance Abuse Treatment* **9**: 15-25.
40. Moffatt S, Weatherburn D & Donnelly N (2005) *What caused the recent drop in property crime?* Sydney: NSW Bureau of Crime Statistics and Research.
41. Gunne LM & Grondbladh L (1981). The Swedish methadone maintenance programme: a controlled study. *Drug and Alcohol Dependence* **7**: 249-56.

42. Rosenbaum M (1985) A matter of style: variation among methadone clinics in the control of clients. *Contemporary Drug Problems* **12**: 375-99.
43. General Accounting Office (1990) *Methadone maintenance: some treatment programs are not effective; greater federal oversight needed. Report to the chairman, Select Committee on Narcotic Abuse and Control, House of Representatives*. Washington DC: General Accounting Office.
44. De Maeyer J, Vanderplasschen W, Camfield L et al (2011) A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals. *International Journal of Nursing Studies* **48**: 1244-57.
45. Bell J, Chan J & Kuk A (1995) Investigating the effect of treatment philosophy on outcome of methadone maintenance. *Addiction* **90**: 823-30.
46. Dyer KR & Foster DJ, White JM et al (1999) Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. *Clinical Pharmacology and Therapeutics* **65**: 685-94.
47. Holmstrand J, Anggard E & Gunne LM (1978) Methadone maintenance: plasma levels and therapeutic outcome. *Clinical Pharmacology and Therapeutics* **23**: 175-80.
48. Mattick RP, Kimber J, Breen C et al (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews* (**2**): CD002207.
49. Bell J, Butler B, Lawrance A et al (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. *Drug and Alcohol Dependence* **104**: 73-7.
50. Mattick RP, Breen C, Kimber J et al (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews* (**3**): CD002209.
51. Neale J (1999) Drug users' views of substitute prescribing conditions. *International Journal of Drug Policy* **10**: 247-58.
52. Bell J, Shanahan M, Mutch C et al (2007) A randomised trial of effectiveness and cost effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. *Addiction* **102**: 1899-907.
53. Barau K, Thirion X, Micallef J et al (2001) Comparison of methadone and high dosage buprenorphine users in French care centres. *Addiction* **96**: 1433-41.
54. Auriacombe M, Fatséas M, Dubernet J et al (2004) French field experience with buprenorphine. *American Journal on Addictions* **13**: S17-S28.
55. Barnett PG, Trafton JA & Humphreys K (2010) The cost of concordance with opiate substitution treatment guidelines. *Journal of Substance Abuse Treatment* **39**: 141-9.
56. McLellan AT, Arndt IO, Metzger DS et al (1993) The effects of psychosocial services in substance abuse treatment. *The Journal of the American Medical Association* **269**: 1953-9.
57. Schwartz RP, Kelly SM, Gandhi D et al (2011) Interim methadone treatment compared to standard methadone treatment: 4-month findings. *Journal of Substance Abuse Treatment* **41**: 21-9.
58. Bell J (1998) Delivering effective methadone treatment. In: Ward J, Mattick RP & Hall W (eds) *Methadone maintenance treatment and other opioid replacement therapies*. Amsterdam: Harwood Academic Publishers.
59. Amato L, Minozzi S, Davoli M et al (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database of Systematic Reviews* (**10**): CD004147.
60. National Institute of Drug Abuse (2002) *Therapeutic community*. Bethesda: National Institute of Drug Abuse.
61. Zhang Z, Friedmann PD & Gerstein DR (2003) Does retention matter? Treatment duration and improvement in drug use. *Addiction* **98**: 673-84.
62. Chan JSK, Kuk AYC, Bell J et al (1998) The analysis of methadone clinic data using marginal and conditional logistic models with mixture or random effects. *The Australian and New Zealand Journal of Statistics* **40**: 1-10.
63. Gossop M, Stewart D, Browne N et al (2003) Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: outcomes at 2-year follow-up. *Journal of Substance Abuse Treatment* **24**: 313-21.
64. Taylor D, Paton C & Kapur S (2009) *The Maudsley prescribing guidelines in psychiatry* (10e). London: Informa Healthcare.

65. McLellan AT, Lewis DC, O'Brien CP et al (2000) Drug dependence, a chronic medical illness implications for treatment, insurance, and outcomes evaluation. *The Journal of the American Medical Association* **284**: 1693.
66. Cornish R, Macleod J, Strang J et al (2010) Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *British Medical Journal* **341**: c5475.
67. National Institute for Health and Clinical Excellence (2011) *Alcohol dependence and harmful alcohol use. Clinical Guideline 115*. London: National Institute for Health and Clinical Excellence.
68. Krupitskya EM & Blokhina EA (2010) Long-acting depot formulations of naltrexone for heroin dependence: a review. *Current Opinion in Psychiatry* **23**: 210-4.
69. Minozzi S, Amato L, Vecchi S et al (2011) Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews* (4): CD001333.
70. Bale RN, Van Stone WW, Kuldau JM et al (1980) Therapeutic communities versus methadone maintenance. *Archives of General Psychiatry* **37**: 179-83.
71. Gerstein DR & Harwood HJ (1990) *Treating drug problems. Volume 1: A study of effectiveness and financing of public and private drug treatment systems*. Washington DC: National Academy Press.
72. Ward J, Hall W & Mattick RP (1999) Role of maintenance treatment in opioid dependence. *The Lancet* **353**: 221-6.
73. Bell J, Burrell T, Indig D et al (2006) Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. *Drug and Alcohol Dependence* **81**: 55-61.
74. Strang J, Manning V, Mayet S et al (2007) Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England 1995-2005. *Addiction* **102**: 761-70.
75. Department of Health, Scottish Government, Welsh Assembly Government and Northern Ireland Executive (2007) *Drug misuse and dependence: UK guidelines on clinical management*. London: Department of Health.
76. Marsden J, Eastwood B, Bradbury C et al (2009) Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. *The Lancet* **374**: 1262-70.
77. Van Ameijden EJC, van den Hoek AAR & Couthino RA (1994) Injecting risk behaviour among injecting drug users in Amsterdam, 1986-1992, and its relationship to AIDS prevention programs. *American Journal of Public Health* **84**: 275-281.
78. Hunt DA, Lipton DS, Goldsmith DS et al (1985-86) 'It takes your heart': the image of methadone maintenance in the addict world and its effect on recruitment into treatment. *International Journal of the Addictions* **20**: 1751-71.
79. Bell J (1995) Lessons from a training programme for methadone prescribers. *Medical Journal of Australia* **162**: 143-4.
80. Strang J, Hall W, Hickman M et al (2010) Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. *British Medical Journal* **341**: c4851.
81. Bell J, Trinh L, Butler B et al (2009) Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. *Addiction* **104**: 1193-200.
82. Davoli M, Bargagli AM, Preucil CA et al (2007) Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. *Addiction* **102**: 1954-9.
83. Bell J, Butler B, Lawrance A et al (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. *Drug and Alcohol Dependence* **104**: 73-7.
84. Strang J, Griffiths P, Powis B et al (1999) Which drugs cause overdose among opiate misusers? Study of personal and witnessed overdoses. *Drug and Alcohol Review* **18**: 253-61.
85. Caplehorn JR & Drummer OH (1999) Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. *Medical Journal of Australia* **170**: 104-9.
86. Caplehorn JR (1998) Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. *Drug and Alcohol Review* **17**: 9-17.
87. Zador D & Sunjic S (2000) Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. *Addiction* **95**: 77-84.
88. Hall W (1999) Reducing the toll of opioid overdose deaths in Australia. *Drug and Alcohol Review* **18**: 213-20.

89. Darke S, Hall W (2003) Heroin overdose: research and evidence-based intervention. *Journal of Urban Health* **80**: 189-200.
90. Williams A, Reed K, Groshkova T et al (2010) Training family members and carers of opiate users in overdose management and naloxone administration: a randomised trial. *Drug and Alcohol Review* **29**: A80.
91. Strang J, Darke S, Hall W et al (1996) Heroin overdose: the case for take-home naloxone? *British Medical Journal* **312**: 1435.
92. Wakeman S, Bowman SE, McKenzie M et al (2009) Preventing death among the recently incarcerated: an argument for naloxone prescription before release. *Journal of Addictive Diseases* **28**: 124-9.
93. National naloxone programme www.scotland.gov.uk (accessed 3 October 2012).
94. NALoxone InVEstigation (N-Alive) pilot randomised controlled trial www.controlled-trials.com (accessed 3 October 2012).

Chapter 9

1. Neale J, Tompkins C & Sheard L (2008) Barriers to accessing generic health and social care services: a qualitative study of injecting drug users. *Health and Social Care in the Community* **16**: 147-54.
2. Barnaby B, Drummond C, McCloud A et al (2003) Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes. *British Medical Journal* **327**: 783-4.
3. Kouimtsidis C, Reynolds M, Hunt M et al (2003) Substance use in the general hospital. *Addictive Behaviours* **28**: 483-99.
4. Abouyanni G, Stevens LJ, Harris MF et al (2000) GP attitudes to managing drug- and alcohol-dependent patients: a reluctant role. *Drug and Alcohol Review* **19**: 165-70.
5. Ryrie I & Ford C (2001) The primary care treatment of drug users: is shared care really the best approach? *Journal of Substance Use* **6**: 3-6.
6. National Institute of Alcohol Abuse and Alcoholism (1999) *Alcohol alert*. Rockville: National Institute on Alcohol Abuse and Alcoholism.
7. Bien TH, Miller WR & Tonigan JS (1993) Brief interventions for alcohol problems: a review. *Addiction* **88**: 315-6.
8. McQueen J, Howe TE, Allan L et al (2011) Brief interventions for heavy alcohol users admitted to general hospital wards. *Cochrane Database of Systematic Reviews* (**8**): CD005191.
9. Walton MA, Chermack ST, Shope JT et al (2010) Effects of a brief intervention for reducing violence and alcohol misuse among adolescents: a randomized controlled trial. *The Journal of the American Medical Association* **304**: 527-35.
10. McLellan AT, Lewis DC, O'Brien CP et al (2000) Drug dependence, a chronic medical illness implications for treatment, insurance, and outcomes evaluation. *The Journal of the American Medical Association* **284**: 1689-95.
11. Booth RE, Crowley TJ & Zhang Y (1996) Substance abuse treatment entry, retention and effectiveness. *Drug and Alcohol Dependence* **42**: 11-20.
12. General Medical Council (2012) *Protecting children and young people. The responsibilities of all doctors*. London: General Medical Council.
13. Gates S, McCambridge J, Smith LA et al (2006) Interventions for prevention of drug use by young people delivered in non-school settings. *Cochrane Database of Systematic Reviews* (**1**): CD005030.
14. Stephens RS, Roffman RA & Curtin L (2000) Comparison of extended versus brief treatments for marijuana use. *Journal of Consulting and Clinical Psychology* **68**: 898-908.
15. Weissa RD, Griffin ML, Gallop RJ et al (2005) The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. *Drug and Alcohol Dependence* **77**: 177-84.
16. McCambridge J & Strang J (2004) The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. *Addiction* **99**: 39-52.
17. Marijuana Treatment Project Research Group (2004) Brief treatments for cannabis dependence: findings from a randomized multisite trial. *Journal of Consulting and Clinical Psychology* **72**: 455-66.
18. National Institute for Health and Clinical Excellence (2007). *Drug misuse: psychosocial interventions. Clinical Guideline 51*. London: National Institute for Health and Clinical Excellence.

19. National Institute for Health and Clinical Excellence (2007) *Drug misuse: opioid detoxification. Clinical Guideline 52*. London: National Institute for Health and Clinical Excellence.
20. Smythe BP, Barry J, Keenan E et al (2010) Lapse and relapse following inpatient treatment of opiate dependence. *The Irish Medical Journal* **103**: 176-9.
21. Ho RCM, Chen KY, Broekman B et al (2009) Buprenorphine prescription, misuse and service provision: a global perspective. *Advances in Psychiatric Treatment* **15**, 354-63.
22. Bell J (2010) The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. *Addiction* **105**: 1531-7.
23. Blackwell J (1988) The saboteurs of Britain's opiate policy: overprescribing physicians or American-style 'junkies'? *International Journal of Addiction* **23**: 517-26.
24. Strang J, Hall W, Hickman M et al (2010) Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. *British Medical Journal* **341**: c4851.
25. Martyres RF, Clode D & Burns JM (2004) Seeking drugs or seeking help? Escalating 'doctor shopping' by young heroin users before fatal overdose. *Medical Journal of Australia* **180**: 211-4.
26. National Institute for Health and Clinical Excellence (2011) *Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guideline 113*. London: National Institute for Health and Clinical Excellence.
27. Sikdar S (1998) Physical dependence on zopiclone: prescribing this drug to addicts may give rise to iatrogenic drug misuse. *British Medical Journal* **317**: 146.
28. Reed K, Bond A, Witton J et al (2011) *The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England: a structured review of published English and international evidence and available data to inform consideration of the extent of dependence and harm*. London: National Addiction Centre, King's College.
29. Schweitzer E & Rickels K (1998) Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. *Acta Psychiatrica Scandinavica* **98**: 95-101.
30. Royal College of Psychiatrists (1997) *Benzodiazepines: risks, benefits or dependence: a re-evaluation*. Council Report 59. London: Royal College of Psychiatrists.
31. Tyrer P (1991) The benzodiazepine withdrawal syndrome. *Stress Medicine* **7**: 1-2.
32. Tarabar AF & Nelson LS (2004) The [gamma]-hydroxybutyrate withdrawal syndrome. *Toxicological Reviews* **23**: 45-9
33. Bell J & Collins R (2011) Gamma-butyrolactone (γ) dependence and withdrawal. *Addiction* **106**: 442-7.
34. American Psychiatric Association (1994) *Diagnostic and statistical manual of mental disorders (4e)*. Washington: American Psychiatric Association
35. Kampman KM, Volpicelli JR, Alterman AI et al (2000) Amantadine in the treatment of cocaine-dependent patients with withdrawal symptoms. *American Journal of Psychiatry* **157**: 2052-4.
36. Shoptaw SJ, Kao U, Heinzerling K et al (2009) Treatment for amphetamine withdrawal. *Cochrane Database of Systematic Reviews* (2): CD003021.
37. Scott JC, Woods SP, Matt GE et al (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. *Neuropsychology review* **17**: 275-97.
38. Meredith CW, Jaffe C, Ang-Lee K et al (2005) Implications of chronic methamphetamine use: a literature review. *Harvard Review of Psychiatry* **13**: 141-54.
39. Galloway GP, Buscemi R, Coyle JR et al (2011) A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. *Clinical Pharmacology and Therapeutics* **89**: 276.
40. Standaert DG & Young AB (1996). Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB et al (eds) *Goodman and Gilman's the pharmacological basis of therapeutics (3e)*. New York: McGraw-Hill.
41. Sofuoglu M, Kosten TR (2005) Novel approaches to the treatment of cocaine addiction. *CNS Drugs* **19**: 13-25.
42. Levin KH, Copersino ML, Heishman SJ et al (2010) Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. *Drug and Alcohol Dependence* **111**: 120-7.
43. Hasin DS, Keyes KM, Alderson D et al (2008) Cannabis withdrawal in the United States: results from NESARC. *Journal of Clinical Psychiatry* **69**: 1354-63.

44. Budney AJ, Hughes JR, Moor BA et al (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. *Archives of General Psychiatry* **58**: 917-24.
45. Haughey HM, Marshall E, Schact JP et al (2008) Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. *Addiction* **103**: 1678-86.
46. Vandrey R & Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? *Drugs* **23**: 543-53.
47. Nordstrom BR & Levin FR (2007) Treatment of cannabis use disorders: a review of the literature. *The American Journal on Addictions* **16**: 331-42.
48. Marsden J (2004) Long-term outcome of treatment for drug dependence. *Psychiatry* **3**: 47-9.
49. Darke S & Hall W (2003) Heroin overdose: research and evidence-based intervention. *Journal of Urban Health* **80**: 189-200.
50. Strang J, McCambridge J, Best D et al (2003) Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow-up study. *British Medical Journal* **326**: 959-60.
51. Nería-León M, Barrio G, Brugal MT et al (2006) Do young heroin users in Madrid, Barcelona and Seville have sufficient knowledge of the risk factors for unintentional opioid overdose? *Journal of Urban Health* **83**: 477-96.
52. Williams A, Reed K, Groshkova T et al (2010) Training family members and carers of opiate users in overdose management and naloxone administration: a randomised trial. Australasian Professional Society on Alcohol and Other Drugs Conference 2010 Paper 122. *Drug and Alcohol Review* **29**: 81.
53. Minozzi S, Amato L, Vecchi S et al (2011) Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews* (4): CD001333.
54. Castells X, Casas M, Pérez-Mañá C et al (2010) Efficacy of psychostimulant drugs for cocaine dependence. *Cochrane Database of Systematic Reviews* (2): CD007380.
55. Carroll KM & Onken LS (2005) Behavioral therapies for drug abuse. *American Journal of Psychiatry* **162**: 1452-60.
56. Lussier J, Heil S, Mongeon J et al (2006) A meta-analysis of voucher-based reinforcement therapy for substance use disorders. *Addiction* **101**: 192-203.
57. Petry NM & Alessi SM (2010) Prize-based contingency management is efficacious in cocaine-abusing patients with and without recent gambling participation. *Journal of Substance Abuse Treatment* **39**: 282-8.
58. Prendergast M, Podus D, Finney J et al (2006) Contingency management for treatment of substance use disorders: a meta-analysis. *Addiction* **101**: 1546-60.
59. Stulza N, Gallop R, Lutz W et al (2010) Examining differential effects of psychosocial treatments for cocaine dependence: an application of latent trajectory analyses. *Drug and Alcohol Dependence* **106**: 164-72.
60. *Who, what, how, and why*
www.na.org/admin/include/spaw2/uploads/pdf/litfiles/us_english/IP/EN3101.pdf (accessed 3 October 2012).
61. Gossop M, Stewart D & Marsden J (2008) Attendance at narcotics anonymous and alcoholics anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. *Addiction* **103**: 119-25.
62. National Institute for Health and Clinical Excellence (2010) *Pregnancy and complex social factors. Clinical guideline 110*. London: National Institute for Health and Clinical Excellence.
63. Department of Health, Scottish Government, Welsh Assembly Government and Northern Ireland Executive (2007) *Drug misuse and dependence: UK guidelines on clinical management*. London: Department of Health.
64. Archie C (1998) Methadone in the management of narcotic addiction in pregnancy (editorial). *Current opinion in Obstetrics and Gynaecology* **10**: 435-40.
65. Johnson RE, Jones HE, Jasinski DR et al (2001) Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. *Drug and Alcohol Dependence* **63**: 97-103.
66. Johnson RE, Jones HE & Fischer G (2003) Use of buprenorphine in pregnancy: patient management and effects on the neonate. *Drug and Alcohol Dependence* **70**: S87-S101.

Chapter 10

1. National Institute for Health and Clinical Excellence (2007) *Methadone and buprenorphine for the management of opioid dependence. Technology Appraisal Guidance 114*. : National Institute for Health and Clinical Excellence.
2. British Medical Association (2012) *Medical ethics today: the BMA handbook of ethics and law*. London: British Medical Association.
3. Royal College of General Practitioners, Royal Pharmaceutical Society & The Secure Environment Pharmacist Group (2011) *Safer prescribing in prisons*. Nottingham: Nottinghamshire Healthcare NHS Trust.
4. Stewart D (2010) Drug use and perceived treatment need among newly sentenced prisoners in and . *Addiction* **104**: 243-7.
5. Singleton N, Meltzer H, Gatward R et al (1998) *Psychiatric morbidity among prisoners in England and Wales*. London: Her Majesty's Stationery Office.
6. Boys A, Farrell M, Bebbington P et al (2002) Drug use and initiation in prison: results from a national prison survey in England and Wales. *Addiction* **97**: 1551-60.
7. Strang J, Gossop M, Heuston J et al (2006) Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. *Addiction* **101**: 1125-32.
8. Skodbo S, Brown G, Deacon S et al (2007) *The Drug Interventions Programme (DIP): addressing drug use and offending through 'Tough Choices'*. London: Home Office.
9. Home Office (2009) *Drug Interventions Programme operational handbook*. London: Home Office.
10. Ramsay M (1997) *Persistent drug-misusing offenders. Research Findings No 50*. : Home Office Research and Statistics Directorate.
11. Davies C, English L, Lodwick A et al (2010) *United Kingdom drug situation: annual report to the European monitoring centre for drugs and drug addiction (EMCDDA) 2010*. London: Department of Health.
12. Weetman R (2012) Getting it right. *Drink and Drugs News*. **January**: 12.
13. Kerr J, Tompkins C, Tomaszewski W et al (2011) *The Dedicated Drug Courts Pilot Evaluation Process Study. Ministry of Justice Research Series 1/11*. : The National Centre for Social Research.
14. General Medical Council (2009) *Confidentiality, guidance for doctors*. London: General Medical Council.
15. Chambers M (2010) *Coming clean: combating drug misuse in prisons*. London: Policy Exchange.
16. Blakey D (2008) *Disrupting the supply of illicit drugs into prisons: a report for the Director General of National Offender Management Service*. London: Ministry of Justice.
17. Ministry of Justice, National Offender Management Service (2008) *The National Offender Management Service Drug Strategy 2008-2011*. London: National Offender Management Service.
18. Ministry of Justice, National Offender Management Service (2005) *Strategy for the management and treatment of problematic drug users within the correctional services*. London: National Offender Management Service.
19. Dolan KA, Shearer J, White B et al (2005) Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* **100**: 820-8.
20. Kinlock TW, Gordon MS, Schwartz RP et al (2009) A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. *Journal of Substance Abuse Treatment* **37**: 277-85.
21. Department of Health (2006) *Clinical management of drug dependence in the adult prison setting including psychosocial treatment as a core part*. London: Department of Health.
22. Farrell M & Marsden J (2008) Acute risk of drug-related death among newly released prisoners in England and Wales. *Addiction* **103**: 251-5.
23. Merrill ELC, Kariminia A, Binswanger IA et al (2010) Meta-analysis of drug-related deaths soon after release from prison. *Addiction* **105**: 1545-54.
24. Sheard L, Wright NMJ, Adams CE et al (2009) The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. *Trials* **10**: 53.
25. Coviello DM, Cornish JW, Lynch KG et al (2010) A randomized trial of oral naltrexone for treating opioid-dependent offenders. *The American Journal on Addictions* **19**: 422-32.

26. Lobmaier PP, Kunøea N, Gossopa M et al (2010) Naltrexone implants compared to methadone: outcomes six months after prison release. *European Addiction Research* **16**: 139-45.
27. Turner KM, Hutchinson S, Vickerman P et al (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* **106**: 1978-88.
28. Wodak A & Cooney A (2006) Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. *Substance Use and Misuse* **41**: 777-813.
29. Larney S (2010) Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. *Addiction* **105**: 216-23.
30. Vescio MF, Longo B, Babudieri S et al (2008) Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *Journal of Epidemiology and Community Health* **62**: 305-13.
31. Rotily M, Weilandt C, Bird SM et al (2001) Surveillance of HIV infection and related risk behaviour in European prisons A multicentre pilot study. *European Journal of Public Health* **11**: 243-50.
32. Stark K, Herrman U, Ehrhardt S et al (2006) A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. *Epidemiology and Infection* **134**: 814-9.
33. United Nations Office on Drugs and Crime, World Health Organization & Joint United Nations Programme on HIV/AIDS (2004) *HIV/AIDS prevention, care, treatment and support in prison settings. A framework for an effective national response*. Vienna: United Nations Office on Drugs and Crime.
34. Herald Scotland (30.03.09) *Prison officers ready to revolt over needle exchange plan*.
35. Department of Health (2011) *Tackling blood-borne viruses in prisons. A framework for best practice in the UK*. London: Department of Health.
36. Scottish Government (2008) *Hepatitis C Action Plan for Scotland Phase II: May 2008-March 2011*. Edinburgh: The Scottish Government.
37. The Scottish Government (2010) *Guidelines for services providing injecting equipment: best practice recommendations for commissioners and injecting equipment provision (IEP) services in Scotland*. Edinburgh: The Scottish Government.
38. Heller-Murphy S (2005) *The direction of harm reduction in the SPS: from chaotic drug use to abstinence*. Aberdeen: Scottish Prison Service.
39. Hutchinson SJ, Wadd S, Taylor A et al (2004) Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. *Vaccine* **23**: 210-4.
40. Hope VD, Ncube F, Hickman M et al (2007) Hepatitis B vaccine uptake among injecting drug users in 1998 to 2004: is the prison vaccination programme driving recent improvements? *Journal of Viral Hepatitis* **14**: 653-60.
41. Health Protection Agency, Department of Health, Social Services and Public Safety, National Public Health Service for Wales, Health Protection Scotland (2009) *Shooting up. Infections among injecting drug users in the United Kingdom 2008. An update: October 2009*. London: Health Protection Agency.
42. Health Protection Agency Prison Infection Prevention Team (2011) *Health protection in prisons report 2009-2010*. London: Health Protection Agency.
43. Daniels AM (1997) Treatment of opiate dependent drug misusers. Doctors in prison must be careful when prescribing methadone. *British Medical Journal* **315**: 603.
44. Gossop M (1990) The development of a short opiate withdrawal scale (SOWS) *Addiction and Behaviour* **15**: 487-90.
45. Seaman SR, Brettell RP & Gore SM (1998) Mortality from overdose among injecting drug users recently released from prison: database linkage study. *British Medical Journal* **316**: 426-8.
46. Nunn A, Zaller N, Dickman S et al (2009) Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. *Drug and Alcohol Dependence* **105**: 83-8.
47. Nunn A (2010) Improving access to opiate addiction treatment for prisoners. *Addiction* **105**: 1312-3.
48. Strang J, Griffiths P, Powis B et al (1999) Which drugs cause overdose among opiate misusers? Study of personal and witnessed overdoses. *Drug and Alcohol Review* **18**: 253-61.
49. Darke S & Hall W (2003) Heroin overdose: research and evidence-based intervention. *Journal of Urban Health* **80**: 189-200.
50. *National Naloxone Programme* www.scotland.gov.uk/Topics/Justice/law/Drugs-Strategy/drugsrelateddeaths/NationalNaloxone (accessed 3 October 2012).

51. *NALoxone InVEstigation (N-Alive) pilot randomised controlled trial* www.controlled-trials.com/ISRCTN34044390 (accessed 3 October 2012).
52. United Nations Office on Drugs and Crime (2006) *Custodial and non-custodial measures. Social reintegration*. New York: United Nations.
53. The Betty Ford Consensus Panel (2007) What is recovery? A working definition from the Betty Ford Institute. *Journal of Substance Abuse Treatment* **33**: 221-8.
54. Oliver P, Keen J, Rowse G et al (2010) The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. *Addiction* **105**: 732-9.
55. Hickman M, Vickerman P, Robertson R et al (2011) Promoting recovery and preventing drug-related mortality: competing risks? *Journal of Public Health* **33**: 332-4.
56. Granfield R & Cloud W (1999) *Coming clean: overcoming addiction without treatment*. New York: New York University Press.

Chapter 11

1. Royal College of Psychiatrists & Royal College of General Practitioners (2012) *Delivering quality care for drug and alcohol users: the roles and competencies of doctors. A guide for commissioners, providers and clinicians. College Report CR173*. London: Royal College of Psychiatrists.
2. General Medical Council (2009) *Good medical practice*. London: General Medical Council.
3. Barnaby B, Drummond C, McCloud A et al (2003) Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes. *British Medical Journal* **327**: 783-4.
4. Intervention Study Group (2003) Attitudes and management of alcohol problems in general practice: descriptive analysis based on findings of a World Health Organization international collaborative survey. *Alcohol and Alcoholism* **38**: 597-601.
5. Degenhardt L, Knox S, Barker B et al (2005) The management of alcohol, tobacco and illicit drug use problems by general practitioners in Australia. *Drug and Alcohol Review* **24**: 499-506.
6. Abouyanni G, Stevens LJ, Harris MF et al (2000) GP attitudes to managing drug- and alcohol-dependent patients: a reluctant role. *Drug and Alcohol Review* **19**: 165-70.
7. Babor T, Caulkins J, Edwards G et al (2010) *Drugs policy and the public good*. Oxford: Oxford University Press.
8. British Medical Association Medical Ethics Department (2012) *Medical ethics today. The BMA's handbook of ethics and law (3e)*. London: British Medical Journal Books.
9. Ziegler PP (2005) Addiction and the treatment of pain. *Substance use and misuse* **40**: 1945-54.
10. General Medical Council (2008) *Good practice in prescribing medicines – guidance for doctors*. London: General Medical Council.
11. Department of Health, Scottish Government, Welsh Assembly Government and Northern Ireland Executive (2007) *Drug misuse and dependence: UK guidelines on clinical management*. London: Department of Health.
12. NHS National Prescribing Centre (2009) *A guide to good practice in the management of controlled drugs in primary care (England)*. Liverpool: National Prescribing Centre.
13. Strang J, Babor T, Caulkins J et al (2012) Drug policy and the public good: evidence for effective interventions. *The Lancet* **379**: 71-83.
14. Inciardi JA, Surratt HL, Kurtz SP et al (2007) Mechanisms of prescription drug diversion among drug-involved club and street-based populations. *Pain Medicine* **8**: 171-83.
15. Falkowski J & Ghodse AH (1989) Undergraduate medical school training in psychoactive drugs and rational prescribing in the United Kingdom. *British Journal of Addiction* **84**: 1539-42.
16. Glass IB (1989) Undergraduate training in substance abuse in the United Kingdom. *British Journal of Addiction* **84**: 197-202.
17. Crome IB (1999) The trouble with training: substance misuse education in British medical schools revisited. What are the issues? *Drugs: Education, Prevention, and Policy* **6**: 111-23.
18. Crome IB & Shaikh N (2004) Undergraduate medical school education in substance misuse in Britain iii: can medical students drive change? *Drugs: Education, Prevention, and Policy* **11**: 483-503.
19. International Centre for Drug Policy (2007) *Substance misuse in the undergraduate medical curriculum*. London: International Centre for Drug Policy.